Melanoma Molecular Maps Projects

Padova

Dermoscopy



1. Introduction

The ABCDE rule (asymmetry, irregular borders, multiple colors, diameter >6 mm, enlarging lesion) contains the main clinical criteria for naked-eye based diagnosis of suspected cutaneous malignant melanoma (CMM). The early phase of malignant melanoma is difficult to identify because CMM can share many clinical features with an atypical nevus. In fact several studies have described diagnostic accuracy rates ranging from 50-75% [1,2], indicating a need for additional diagnostic tools, in particular to detect the so-called small melanomas as well as melanoma regular in shape or color [3-5].
Over the last 20 years, dermoscopy (i.e. dermatoscopy, epiluminescence microscopy [ELM], surface microscopy) has opened a new dimension in the examination of pigmented skin lesions (PSL) and, especially, in the identification of the early phase of CMM [3-33].

Dermoscopy is a non-invasive method that allows the in vivo evaluation of colors and microstructures of the epidermis, the dermo-epidermal junction, and the papillary dermis not visible to the naked eye (FIGURE 1). These structures are specifically correlated to histological features [5,6].
The identification of specific diagnostic patterns related to the distribution of colors and dermoscopy structures can better suggest a malignant or benign PSL.
Based on the results of meta-analyses, dermoscopy is more accurate than clinical examination in the diagnosis of pigmented skin lesions [8,9]. However this technique must be considered as a valid support, but not a substitute, in the clinical diagnosis of melanoma [5,29-32].


FIGURE 1: Clinical (upper panel) and corresponding dermoscopic image (lower panel) of a melanocytic nevus. Dermoscopy shows symmetry in pigmentation and structures throughout the lesion with globules symmetrically distributed at periphery.





2. Technique

Dermoscopy involves the evaluation of the skin surface. During a dermoscopy assessment, the PSL is covered with a liquid (usually oil or alcohol) and examined under a specific optical system. Applying oil reduces the reflectivity of the skin and enhances the transparency of the stratum corneum. This allows visualization of specific structures related to the epidermis, the dermo-epidermal junction and the papillary dermis, and it also suggests the location and distribution of melanin (FIGURE 1).
Numerous instruments (FIGURE 2) are utilized for dermoscopic examination, such as conventional contact dermoscope, contact polarized light dermoscope, non-contact polarized light dermoscope, stereomicroscope, videodermoscope, digital camera. These instruments and the corresponding techniques can be equivalent and/or complementary and can influence the inter- and intra-observer reproducibility [10-15].


FIGURE 2: Dermoscopy instruments (in order of appearance, from top to bottom): dermatoscope; hand held stereomicroscope; stereomicroscope; digital epiluminescence by stereomicroscope; videomicroscope; digital camera.











2.1. Dermatoscope

The dermatoscope is the standard piece of equipment used to perform a dermoscopy examination (FIGURE 2). It is similar to an otoscope, is user friendly, and is inexpensive. These optical system's features include monocular observation, 10x magnification, and the use of an illumination system (3.5-V halogen lamp).
Recently the use of dermoscope with light-emitting diode (LED) lighting and polarizing filters for glare reduction eliminates the need for skin contact and the required liquids. Although these latter instruments are very useful for rapidly screening pigmented lesions in patients with multiple nevi, the clinical images can be different from those attained using conventional glass plate liquid-surface microscopes. For these reasons it has been suggested to use cross-polarized surface to rapid screening of pigmented lesions, with a final definitive diagnosis dependent on glass plate liquid instruments.
Furthermore digital epiluminescence microscopy system combined with a digital camera can capture a high quality, glare-free image (FIGURE 2).
Documenting lesions is simple for training, teledermoscopy, pre-surgical evaluation and mole mapping.


2.2. Stereomicroscope

Another optical instrument, the stereomicroscope, allows for an accurate binocular observation with different magnifications (6x-80x) (FIGURE 2).
The illumination system includes a halogen lamp (12 V/50 W).
From an empiric point of view, visualization is better than with the dermatoscope, but formal studies of the differences in diagnostic features and accuracy of the two instruments have never been published.


2.3. Videodermatoscope

Features of another optical system, the videodermatoscope, include a video probe that transmits images of the PSL to a color monitor (FIGURE 2).
The addition of a digital system to the stereomicroscope (also termed the digital epiluminescence microscope) or to the videodermatoscope has opened a new area in the field of skin cancer diagnosis with the advantages of computerized technology.
However, the technologic features (which are cost dependent) of the camera (single-chip video charge-coupled device, 3-chip charge-coupled device, or still digital), optical system, monitor, digitized board, and software significantly influence the resolution and quality of the images.


3. Color

Accurate evaluation of the PSL color, degree of pigmentation and distribution of the colors within the lesion are the most important elements of a dermoscopy examination.
The epidermis usually appears white, but acanthosis results in a grayish-brown or brownish-yellow color.
Melanin is the most important pigment in determining different structural and chromatic patterns. The PSL can have a different degree and distribution of pigmentation depending on the location of melanin in different layers of the skin.
Melanin location determines the color of the lesion according to the following schema (FIGURE 3):

- Epidermis ==> BLACK
- Dermo-epidermal junction ==> BROWN
- Dermis ==> BLUE

Other possible colors include various shades of white and red (FIGURE 4). White shades are related to regression and may be seen with melanomas, benign melanocytic nevi (halo nevus), and non-melanocytic lesions (lichenoid keratosis, scars). Red shades are related to increased angiogenesis in tumors, an increased number of capillary vessels, and bleeding within the lesion. If bleeding persists and crust develops, the color ranges from red-black to blue-black.
A good evaluation of colors and their relative distribution is essential for achieving the correct clinical diagnosis of a PSL.


FIGURE 3: Pigmented skin lesion (PSL) colors (in order of appearance, from top to bottom): black nevus (intraepidermal location); light-brown nevus (dermo-epidermal junction); dark-brown nevus (dermo-epidemal junction); blue nevus (dermis).








FIGURE 4: Pigmented skin lesion (PSL) colors (in order of appearance, from top to bottom): white (regression); milky red-white (regression + angiogenesis); red (angiogenesis); red-black (hemorrhage).







4. Dermoscopy features

Dermoscopy features (TABLE 1) can be divided into primary and secondary melanocytic and non-melanocytic structures, which show numerous different manifestations related to chromatic and geometric variables (e.g., distribution, width, and caliber).


4.1. Primary structures for melanocytic lesions

4.1.1. Pigment network

The most important epiluminescence microscopy (ELM) feature of melanocytic lesions is the pigment network (PN), which consists of pigmented network lines and hypopigmented holes.
This feature is correlated histologically to the length of the "rete ridges" and to the distribution of melanin within the keratinocytes of the epidermal "rete ridges". The network of hypopigmented holes corresponds to the suprapapillary plate, which is relatively thin and contains less melanin. The network lines correspond to the "rete ridges", which are thicker and have a greater quantity of melanin.
In normal melanocytic nevi, the PN is slightly pigmented. Light-brown network lines are thin and fade gradually at the periphery. Holes are regular and narrow (FIGURES 5-9). The distribution is symmetric and sometimes accentuated in the center of the lesion (FIGURES 10, 11).
In cutaneous malignant melanoma (CMM), the PN usually ends abruptly at the periphery and has irregular holes, thickened and darkened network lines, and tree-like branching at the periphery (FIGURES 12, 13). Moreover, in CMM the PN features change between different sectors of the PSL edge (border): some areas of malignant lesions manifest as a broad and prominent PN, while others have a discrete irregular PN; the PN may also be totally absent in some areas (FIGURES 12, 13).
Clinically atypical nevi (i.e., the nevi defined as dysplastic nevi at pathology evaluation) are often identified because they show areas of irregular and discrete PN distributed asymmetrically (FIGURES 14, 15).


FIGURE 5: Typical pigment network of melanocytic nevus: thin light-brown network lines with holes regular and narrow.


FIGURE 6: Typical pigment network of melanocytic nevus: brown network lines with holes regular and narrow. Color distribution is symmetric.


FIGURE 7: Typical pigment network of melanocytic nevus: thin light-brown network lines with holes regular and narrow. Perilesional skin shows subtle indefinite pigment network a swell as in sunburned fair skinned people.


FIGURE 8: Typical pigment network of melanocytic nevus: brown network lines with holes regular and narrow. The lines fade gradually at the periphery.


FIGURE 9: Typical pigment network of melanocytic nevus: dark-brown pigment network and symmetrical color distribution.


FIGURE 10: Typical pigment network of melanocytic nevus: brown pigment network with darker pigmentation at center of the lesion.


FIGURE 11: Typical pigment network of melanocytic nevus: dark-brown pigment network symmetrically distributed in a dark skinned patient.


FIGURE 12: In situ melanoma: asymmetrical color distribution, atypical pigment network, paracentral blotches suggest strongly a multicomponent pattern related to severe melanocytic atypia.


FIGURE 13: In situ melanoma: multicomponent pattern shows colors and pigment network asymmetrically distributed. Pigment dots (*) are randomly located and differ in size. These atypical structures are related to severe dysplasia at pathology assessment.


FIGURE 14: Atypical pigment network of dysplastic nevus: atypical dark-brown pigment network with prominent and thick lines focally.


FIGURE 15: Dysplastic nevus: this melanocytic lesion shows atypical pigment network branched streaks, peripheral pigment dots and white area (°).



4.1.2. Pseudopigmented network

ELM features of homogeneous pigmentation interrupted by hypopigmented hair follicles and hypopigmented sweat gland openings create a pseudopigmented network.
In benign lesions, this pseudonetwork tends to be uniform and symmetric in color and pattern (FIGURES 16, 17).
By contrast, in lentigo maligna and lentigo maligna melanoma (LMM) the pseudonetwork becomes non-uniform and asymmetric in color and pattern because of the increased number of atypical melanocytes extending along the hair follicles and adnexal structures (FIGURE 18). The meshes become broader, and the holes are larger.


FIGURE 16: Pseudopigmented network of a nevus located on the face. This structure is characterized by a homogeneous pigmentation interrupted by hypopigmented hair follicles.


FIGURE 17: Another example of typical pseudopigmented network of a nevus located on the face.


FIGURE 18: Malignant lentigo: naked eye (upper panel) and dermoscopy (lower panel) view. The atypical pseudopigmented network is asymmetric in color and pattern.



4.1.3. Radial streaming and pseudopods

Radial streaming and pseudopods are different morphologic expressions of malignant melanoma, specifically melanoma in the radial growth phase.
Radial streaming (FIGURE 19) is a linear extension of pigment at the periphery of a lesion, often appearing in groups of nearly parallel, radially arranged linear structures. Depth determines the colors, which are brown, dark brown, blue-gray, and black.
Pseudopods (FIGURE 20) are curved finger-like projections that are predominantly dark brown or black and are located at the periphery of a lesion. They occasionally have small knobs at their tips.
Radial streaming and pseudopods histologically correspond to confluent junctional nests of dysplastic melanocytes.


FIGURE 19: Microinvasive melanoma: multicomponent pattern with black color irregularly distributed. The pigmentation is associated to blue-whitish veil (*) and radial streaming/pseudopods at periphery (circled area): these structures are related to severe melanocytic dysplasia.


FIGURE 20: In situ melanoma: radial streaming at periphery (*) and pseudopods (circled area).




4.1.4. Globules

Pigmented globules are round or oval, dark brown or black, and larger than 1 mm in diameter.
They are uniform in normal PSL, whereas they vary in size, color, and shape in atypical nevi (FIGURE 21) and melanoma. When abundant, aggregated globules have a cobblestone pattern (FIGURE 22), which is typical of benign melanocytic lesions (FIGURES 23, 24).
In CMM, globules are dark or slate blue and are distributed irregularly (FIGURE 25).
Occasionally, isolated dark globules are seen at the margins of achromic lesions: in this case, a diagnosis of melanoma is suggested.
Pigmented globules correspond histologically to nests of pigmented melanocytes (nevus or melanoma) at the junction in the papillary dermis or, because of melanin storage, in melanophage clusters in the papillary dermis.
Milky-red globules can be seen in CMM, representing melanoma cell nests with increased vascularization.


FIGURE 21: Dysplastic nevus: melanocytic nevus with atypical pigment network and focal irregular distribution of globules at periphery.


FIGURE 22: Melanocytic nevus with typical globular pattern also called "cobblestone".


FIGURE 23: Melanocytic nevus with typical globular pattern.


FIGURE 24: Melanocytic nevus with homogeneous brown color at center and regular distribution of globules at periphery.


FIGURE 25: Invasive melanoma: peripheral globules and dots varied in size and colors and irregularly distributed.




4.2. Secondary structures

4.2.1. Dots

Pigmented dots are small, round or irregularly shaped pinpoint structures that are black or dark brown. They correspond to focal accumulations of free melanin or an increased number of highly pigmented melanocytes in the cornified layers of the epidermis.
The presence of melanophages and/or atypical melanocytes in the dermis correlates with blue-gray or slate blue dots and is typically found in pigmented melanocytic and non-melanocytic lesions undergoing regression.
Vertical capillaries found on apical dermal papillae appear as red dots on the palms and soles; sweat gland openings appear as white dots.
In benign melanocytic lesions, dots in the center of the lesion are homogeneous in color and are regular in size, shape, and distribution (FIGURE 26).
In CMM or in atypical lesions, dots may occur at the periphery of the lesion and are irregular in size, shape, and distribution (FIGURES 25, 27).


FIGURE 26: Melanocytic nevus: dark-brown dots (*) homogeneous in color and regular in size, shape and distribution.


FIGURE 27: Microinvasive melanoma: multicomponent pattern mainly characterized by regression phases (white and gray areas **). Other features include irregular vascular pattern (red arrow), pigmented dots (*) and globules (°) irregular in size and randomly located.




4.2.2. Blue-white veil

A blue-white veil is a ground-glass area of pigmentation that is blue-gray to blue-white in color.
This ELM feature is present in homogeneously pigmented black or dark brown lesions and is associated with thickening of the epidermis.
It is correlated histologically with compact orthokeratosis and hypergranulosis, with confluent nests of heavily pigmented melanocytes in the dermis.
A blue-white veil is often found in melanomas (FIGURE 28) and Spitz nevi (FIGURE 29).


FIGURE 28: Invasive melanoma: blue-whitish veil and gray blue areas with black dots ("peppering").


FIGURE 29: "Starburst" pattern in a Reed nevus with blue-whitish veil and radial streaming symmetrically oriented at periphery.




4.2.3. Blue-gray areas

Blue-gray areas are ELM features with coloration varying from gray-blue to deep gray.
Blue-gray or bluish areas may be either isolated disseminated granules or peppering and ill-defined spots with bizarre margins (FIGURES 28, 30).
They may be associated with melanoma regression and are correlated histologically with the presence of melanin and/or hemosiderin within melanocytes and melanophages, and blue-gray areas may be free in the papillary and middle dermis.


FIGURE 30: Regressive areas (blue-gray areas with gray granules [*]) in an atypical melanocytic nevus with histological regression.




4.2.4. Steel blue areas

Steel blue areas are structureless, gray-blue, and homogeneously diffuse.
They are found in blue nevi (FIGURE 31) and occasionally are associated with globules, dots, or both.


FIGURE 31: Blue nevus: homogeneous pattern with blue-steel areas.




4.2.5. Depigmentation

Depigmentation depends on a lack or reduction of pigment in the PSL.
With depigmentation, differentiation can occur in hypopigmented regions that correspond to pigmented areas lighter than other areas within the nevus (FIGURE 32). Differentiation also can occur in white areas that correspond to well-defined white (FIGURES 27, 30) or milky red-white areas related to regressive phase of melanocytic lesions (FIGURE 33).
In contrast to hypopigmented areas, depigmented areas completely lack pigment: histologically, they correspond to fibroplasia, telangiectasias, and loss of melanin.


FIGURE 32: Hypopigmented areas in a melanocytic nevus.


FIGURE 33: Regressive phase as milky red-white areas in invasive melanoma.




5. Main structures of non-melanocytic lesions

5.1. Milia-like cysts

Milia-like cysts are small, circular, whitish-yellow areas with sizes ranging from 0.1-1 mm (FIGURE 34).
They are important for the diagnosis of seborrheic keratosis but can also be found in papillary melanocytic nevi and melanoma, although in seborrheic keratosis, they are larger.
Histologically, milia-like cysts correspond to keratin-filled cysts.


FIGURE 34: Milia-like cysts (*) and comedo-like openings (°) in a seborrheic keratosis.




5.2. Comedo-like openings

Comedo-like openings are another typical diagnostic feature of seborrheic keratosis.
They are keratin-filled pore-like openings that communicate with the surface of the lesion, and are correlated histologically with keratin within the invaginations of the epidermis.
They appear yellow-brown, with a circular or oval shape and a light round halo (FIGURE 35).


FIGURE 35: Comedo-like openings (*) in a seborrheic keratosis.




5.3 Red-black lagoons

Red-black lagoons are the pathognomonic diagnostic criteria of hemangioma and angiokeratomas.
They are small, well-defined, oval or round areas that range from blue-red to blue-black (FIGURE 36).
Histologically, they correspond to large lagoons and thrombi within the vascular spaces of papillary dermis.
Subungual hemorrhages can have blue-red and/or red-black homogeneous pigmentation without vascular lagoons (FIGURE 37).


FIGURE 36: Angioma: red vascular lagoons. Naked-eye (upper panel) and dermoscopic (lower panel) view.



FIGURE 37: Subungueal hemorrhage: naked-eye (upper panel) and dermoscopic (lower panel) view.





5.4. Maple leaf-like pigmentation

Maple leaf-like pigmentation, an important diagnostic criterion for basal cell carcinoma (BCC), is gray-brown to gray-black with a shape similar to that of a maple leaf or to the fingers of a hand (FIGURE 38).
This appearance, combined with the presence of pigmented structures, may simulate CMM (FIGURE 38).
Histologically, they correspond to heavily pigmented basaloid cells within the nest of basal cell carcinoma.


FIGURE 38: Maple leaf-like pigmentation (*) in a basal cell carcinoma (BCC). Tree like vascular vessels are central located.




6. Vascular patterns

Vascular patterns are important markers for melanocytic and non-melanocytic lesions [17-33].
The vascular pattern can be evaluated more accurately using magnification higher than 10x.
Vascular pattern can present in the following ways:

- Tree-like vessels are described as thick, branching vessels; they are compatible with pigmented basal cell carcinoma of any type (FIGURES 38, 39).

- Corona vessels are thinner and less curved than treelike vessels. Generally, they surround a sebaceous gland hyperplasia (FIGURE 40).

- Comma-shaped vessels are parallel to the skin surface and appear as short, strong, curved vascular structures often visible in the dermal nevi (FIGURE 41).

- Dotted vessels are short capillary loops visible as pinpoint dots. They are commonly seen in all types of melanocytic tumors and superficial epithelial tumors (i.e., actinic keratosis (FIGURE 42); Bowen disease).

- Hairpin vessels are long capillary loops of thicker tumors and are related to angiogenesis of thick melanomas (at the border) but also squamous cell carcinoma, keratoacanthoma, and seborrheic keratosis.

A combined presence of linear and other types of vascular features (called linear irregular vessels) is often seen in melanoma (FIGURE 43).


FIGURE 39: Vascular pattern: tree-like vessels (basal cell carcinoma).


FIGURE 40: Vascular pattern: corona vessels (sebaceous hyperplasia).


FIGURE 41: Vascular pattern: comma-shaped vessels (dermal nevus).


FIGURE 42: Vascular pattern: dotted vessels (actinic keratosis).


FIGURE 43: Vascular pattern: dotted vessels (°) and linear irregular vessels (*) in a case of invasive melanoma.





TABLE 1: Dermoscopic features of skin lesions.

Dermoscopic feature

Definition

Clinical diagnosis

Regular pigment network

Network of brownish lines regularly meshed

Melanocytic nevus

Atypical pigment network

Black or gray network with irregular meshes and thick lines

Dysplastic nevus or melanoma

Regular dots & globules

Black, brown or gray round to oval variously sized structures regularly distributed within the lesion

Melanocytic nevus

Atypical dots & globules

Black, brown or gray round to oval variously sized structures irregularly distributed within the lesion

Dysplastic nevus or melanoma

Streaks

Irregular linear structures not clearly combined with pigment network lines

Dysplastic nevus or melanoma

Blue whitish veil

Irregular confluent grey-blue pigmented areas

Dysplastic nevus or melanoma

Regression

White (scar-like) or blue (pepper-like) areas or their combination

Dysplastic nevus or melanoma

Milia-like cysts

White-yellowish dots

Seborrheic keratosis

Comedo-like openings

Brown-yellowish round to oval sharply circumscribed structures

Seborrheic keratosis

Leaf-like areas

Brown-gray to gray-black patches with leaf-like shape

Basal cell carcinoma

Vascular structures

Comma-like vessels

Melanocytic nevus


Arborizing vessels

Basal cell carcinoma


Hairpin vessels

Seborrheic keratosis


Dotted or irregular vessels

Dysplastic nevus or melanoma




7. Diagnostic procedures

Dermoscopy recognition of suggestive melanomas is based on the observation of multiple parameters, as none of these factors is pathognomonic for melanoma.
Many different systems have been proposed for dermoscopy-based classification/diagnosis of suspected PSL, the main aim being of providing clinicians with a practical tool to decide whether or not the PSL should be removed (and histologically evaluated) or just left in place (and followed up if needed).
The most widely used ELM procedures are Pattern Analysis [3], the ABCD Dermoscopy Rule [23], the Menzies score [22], the 7-Point Checklist [21], and the Stratification of Risk Level method (24).


8.1. Pattern analysis

Described by Pehamberger et al. [3] and then redefined by the Consensus Net Meeting on Dermoscopy (CNMD) [20], Pattern Analysis is the procedure most widely used by dermatologists.

Pattern Analysis uses a process of diagnostic framing that keeps control of the known analytic data of all the dermatoscopic parameters of PSL and of the prevalence of single variables: that is, it helps determine whether the PN is present or absent, and - should the PN is present - whether it is typical or atypical (according to the features above discussed).

The various types of PSL (with particular regard to the differentiation between benign and malignant melanocytic lesions) can be determined through Pattern Analysis of specific dermatoscopic features.
The two steps in the new process of Pattern Analysis are the following:
1) to decide whether the lesion is melanocytic or non-melanocytic;
2) to identify the melanocytic lesion, making a diagnosis, and planning relative management.

Pattern Analysis has been deemed superior to the other algorithms (i.e., ABCD Dermoscopy Rule, Menzies score, 7-Point Checklist) for diagnostic efficiency by experts from all over the world in the 2000 CNMD [20].


9.1.1. Pattern analysis: step-1

The first step (FIGURE 44) to identify a melanocytic lesion is to search for the presence of aggregated globules (FIGURE 23), pigment network (PN) (FIGURE 8), or branched streaks (i.e., fragmented irregular PN) (FIGURE 45).
If the above patterns are absent, other characteristics should be sought (substeps).
First, it should be noted that a typical marker for blue nevus is the presence of homogeneous steel blue areas (FIGURE 31).
Second, the lesion should be evaluated for the presence of moth-eaten borders, fingerprinting, comedo-like openings, and milia-like cysts: in this case, the lesion is suggestive of either a solar lentigo (FIGURE 46) or a seborrheic keratosis (FIGURE 34).
Third, if red or red-blue to black lagoons are present, the lesion should be considered a hemangioma (FIGURE 36) or an angiokeratoma.
Finally, the lesion should be evaluated for maple leaf-like structures, arborizing telangiectasias, spoke-wheel-like areas, and gray-blue ovoid nests: this appearance is compatible with a basal cell carcinoma (FIGURE 38).

All lesions should be reevaluated to determine if they have a melanocytic structure, even if they do not have the structures described above.


FIGURE 44: Pattern analysis.


FIGURE 45: Reticular pattern: presence of branched streaks (fragmented irregular pigment network) in an atypical melanocytic nevus.


FIGURE 46: Solar lentigo with moth-eaten borders.




9.1.2. Pattern analysis: step-2

The main goal for step-2 is to make an accurate differential diagnosis between benign melanocytic lesions and melanomas.
The important features in distinguishing these two groups are the overall general appearance of color, architectural order, symmetry of pattern, and homogeneity, also known by the acronym CASH [26].
Melanocytic nevi have few colors, a regular design, and symmetrical patterns (FIGURE 47). In contrast, malignant melanoma often has several colors, architectural disorder, asymmetrical patterns, and heterogeneity (FIGURE 48).

According to the CNMD [20], Pattern Analysis differentiates the general ELM characteristics as "global features" and the dermoscopy guidelines called "local features" are simplified and reduced.
The main global dermoscopic features of melanocytic nevi are characterized by a reticular or globular or cobblestone (globules symmetrically and evenly distributed in the lesion) or homogeneous pattern. The melanocytic lesion appears to have, in this case, a diffuse pigmentation, which might be brown, gray blue, gray-black, or reddish-black and no other dermoscopy structure is found.

The so-called starburst pattern is characterized by the presence of streaks, generally pseudopods visible at the periphery of the lesion radially distributed. In Reed nevi or Spitz nevi this pattern is commonly seen.

Due to the particular anatomy of the palms and soles, the parallel pattern is exclusively found there.
Multicomponent pattern is the combination of three or more distinctive dermoscopic structures (i.e., network, dots, globules and multifaceted areas of different degree of pigmentation) within a given lesion. This pattern strongly suggests a malignant melanoma but might also be seen in some cases of melanocytic nevi and congenital nevi.


FIGURE 47: Pattern analysis: presence of one color, a regular design and a symmetrical pattern in benign nevi.




FIGURE 48: Multicomponent pattern: presence of several colors, atypical pigment network, black dots varied in size, regression areas in melanoma. Architectural disorder, asymmetry of pattern and color are closely related to malignancy.




10. Diagnostic algorithms

The diagnostic algorithms described below can be utilized exclusively after the lesion has been diagnosed as a melanocytic lesion. Use of these algorithms is usually recommended for less expert operators and improves self-training in dermoscopy evaluation.
The CNMD has reported the usefulness and validity of the ABCD Dermoscopy Rule, Menzies Score and 7-Point Check List [20], which are below described.


10.1 ABCD dermoscopy rule

The ABCD Dermoscopy Rule (Stolz method) addresses quantitatively the issue of whether the selected melanocytic lesion is benign, suspicious (borderline) or malignant [23].
The criteria were defined by multivariate analysis and are related to the clinical ABCD rule for diagnosis of PSL (A = asymmetry, B = border, C = color, and D = different structures) (FIGURE 49).
A scoring system was developed using these criteria (FIGURE 50): it calculates the total dermoscopy score (TDS) using a linear equation. With the TDS, a grading of the lesions is possible with respect to their malignant potential (FIGURE 51).

It has been shown that relatively inexperienced operators can more accurately assess melanocytic lesions using this method.

A user-friendly calculator of the TDS is available in this website just by clicking the following link:


MMMP: Total Dermoscopy Score


Asymmetry (A):
For the asymmetry evaluation, the lesion is bisected by two perpendicular axes positioned to produce the lowest possible asymmetry score. Importantly, it is advisable to incorporate also color and structural asymmetry into this ELM parameter because most equivocal lesions have a symmetrical contour (FIGURE 52). Thus, asymmetry must be calculated according to the distribution of colors and structures on either side of each axis, and not solely based on contour, as in the clinical ABCD rule (i.e., during naked-eye evaluation).

Borders (B):
The emphasis is borders that brusquely interrupt at the periphery (FIGURE 52). The lesion is visually divided into 8 pie-shaped segments, and then the number of segments is counted in which an abrupt cut-off is present at the margins of the pigment pattern. The score can range from 0-8.

Colors (C):
The different colors of the lesion are evaluated (FIGURE 52). They include red, white, light and dark brown, blue-gray, and black. White should be counted only if it is lighter than the surrounding skin (white areas) and should not be confused with the hypopigmentation commonly seen in all types of melanocytic lesions. Each color is assigned one point, and the total score ranges from 1 to 6.

Different structural components (D):
The different structural components are examined (FIGURE 52). These components include the PN, branched streaks (thickened and branched PN anywhere in the lesion, not only at the borders), structureless or homogeneous areas (color, but no structures such as PN, branched streaks, dots, or globules), dots, and globules. In order to be counted, structureless or homogeneous areas must be larger than 10% of the lesion.


FIGURE 49: ABCD dermoscopy rule.


FIGURE 50: Total dermoscopy score (TDS).


FIGURE 51: TDS interpretation.


FIGURE 52: TDS examples: Clark nevus (upper panel) and cutaneous malignant melanoma (lower panel).





10.2. Menzies scoring method

Menzies scoring method is another effort to simplify the pattern analysis ELM system [22].
This classification identifies two negative aspects and nine positive aspects commonly used in the semeiotics of dermoscopy.
To make a diagnosis of melanoma, two negative aspects (negative features) must be absent from the lesion, and one or two positive aspects (among the nine positive features) must be present (FIGURE 53).


FIGURE 53: Menzies’ method.




10.2.1. Negative features

The symmetry of the pattern is related to the symmetry of the melanocytic lesion.
Homogeneity of color (i.e., a single color) is observed (FIGURE 54).


10.2.2. Positive features

A blue-white veil appears as irregular, confluent, structureless, blue pigmentation with an overlying ground-glass or hazy appearance (FIGURE 54).
Multiple brown dots appear as focal collections of multiple, dark brown dots, not to be confused with the dark brown globules that are larger and are commonly found in benign nevi.
Peripheral black dots and globules appear as black dots and/or globules found at or near the periphery of a lesion.
Radial streaming is observed.
Pseudopods can be considered variations of the fourth criterion. They are radially oriented or bulbous, fingerlike extensions of the PN at the periphery of a lesion. They should not be scored if they are seen regularly or symmetrically around the lesion.
Scar-like depigmentation (white scar-like area) appears white or milky-white and represents true scarring.
Multiple (5-6) colors are observed, including black, gray, blue, red, dark brown, and tan. White is not counted as a color.
Multiple blue or gray dots appear as foci of multiple "pepper-like" small, blue or gray dots. They are irregular in size and shape (not globules) in the regression areas.
A broadened network shows a localized, thickened, and irregular PN.


FIGURE 54: Examples of Menzies’ method application: melanocytic nevus (upper panel) and cutaneous melanoma (lower panel).




10.3. Seven points checklist

Developed by Argenziano and colleagues [20], the 7-Point Checklist is another variation of the qualitative pattern analysis system, but with a score system.
This method uses 7 criteria specific for melanoma. It includes 3 major criteria (2 points are attributed to each of them), and 4 minor criteria (1 point is attributed to each of them) (FIGURE 55).
This method has fewer criteria to be identified and analyzed as compared to the Pattern Analysis method.
A score of 3 or greater is associated with a high likelihood of melanoma diagnosis at pathology evaluation.


FIGURE 55: Seven-point checklist.




10.3.1. Major criteria

Atypical PN: Black, brown, or gray thickened and irregular line segments are observed anywhere in a lesion (FIGURE 56).
Blue-whitish veil: Irregular, confluent, gray-blue to whitish-blue diffuse pigmentation is observed that can be associated with PN alterations, dots/globules, or streaks. This differs from the Menzies definition, in which the blue color should be featureless.
Atypical vascular pattern: Linear-irregular and/or dotted red vessels are not seen in regression areas.


10.3.2. Minor criteria

Irregular streaks: pseudopods or radial streaming are irregularly arranged at the periphery of the lesion (FIGURE 56).
Irregular pigmentation: black, brown, or gray featureless areas with an irregular shape and/or distribution are observed.
Irregular dots/globules: black, brown, or gray; round to oval; variously sized structures are irregularly distributed in the lesion.
Regression structures: white scar-like areas and/or blue pepper-like areas are observed.


FIGURE 56: Examples of 7-Point checklist application: melanocytic nevus (upper panel) and cutaneous melanoma (lower panel).




10.4 Stratification of risk level

Described by Kenet and Fitzpatrick [24] in 1994 and recently revised by the Melanoma Cooperative Group [25], this method appears to provide very simple and standardized management of both the diagnosis and therapy of early melanomas and suggestive melanocytic lesions.
The stratification of risk level is the basis for the management of melanocytic pigmented lesions (FIGURE 57).
This classification system is based on a wide database of 61,000 examined cutaneous lesions, with 478 diagnosed as cutaneous melanomas (62% stage I, per the American Joint Committee on Cancer) [25].
It is characterized by five risk levels essentially correlated to the history (as described by the patient) and clinical course of the lesion, the presence or absence of a PN, the different variables of the PN associated with the lesion, and other ELM structures (FIGURE 58).

The stratification risk level includes the following three integrated steps [24,25]:

A) History and clinical evaluation: Genetic factors, including melanoma susceptibility, and a suggestive clinical history (i.e., lesion recently changed shape or dimension) should alert the clinician. After a full body evaluation of the skin, PSL are first classified by the clinical ABCDE rules (i.e., asymmetry, irregular border, different colors, diameter > 6 mm, evolution [significant changes over a short period of time, usually months]) as visible by the naked eye. After this first step, all PSL showing at least two ABCDE criteria and a suggestive family or clinical history should be evaluated using dermoscopy.

B) Dermoscopy evaluation, first analysis: A preliminary ELM evaluation should be performed to classify PSL as either non-melanocytic lesions or melanocytic lesions, using the same criteria according to previous guidelines. Melanocytic lesions must be further subclassified in order to plan the best diagnostic strategy.

C) ELM evaluation, second level evaluation for risk-related classification of melanocytic lesions: Melanocytic lesions are classified as very-low, low, medium, high, and very-high risk lesions on the basis of accurate assessment of structural and morphological parameters. The characteristics and classification of individual lesions is based on the presence or absence of dermoscopy melanocytic features.

• Type 1 is considered very high risk. These lesions are suspected of being melanoma because they demonstrate dermoscopy features typical for melanoma.

• Type 2 is considered high risk. These are atypical nevi or borderline lesions that, in most cases, present with an irregular network and other features, such as pseudopods or radial streaming.

• Type 3 is considered medium risk. These are lesions with a PN showing the subtle perturbations that may be present in atypical nevi and lesions with melanocytic hyperplasia. The detection of slight alterations can make diagnosis more difficult, lead to overestimation of the seriousness of a lesion, and result in unnecessary surgery. Clinical history and evaluation findings are important aids to avoid "overdiagnosis".

• Type 4 is considered low risk. These are PSL with benign-appearing networks.

• Type 5 is considered very low risk. These include lesions with a benign-appearing network and with a globular or other benign ELM pattern.

The Melanoma Cooperative Group emphasizes that anamnesis, clinical observation, and other additional parameters be integrated into dermoscopy evaluations for the stratification of risk level in order to standardize the management of melanocytic lesions.


FIGURE 57: Risk level stratification.


FIGURE 58: Examples of risk level stratification application: melanocytic nevus (upper panel) and cutaneous melanoma (lower panel).





11. Practical approach to the management of a PSL

The different dermoscopy classifications have their own worthy internal coherence; however, the use of the different diagnostic scores can be affected by inter-observer and intra-observer variability when only a single guideline is used for evaluation (i.e., limited qualitative and quantitative agreement). Furthermore, all of these classifications can prove to be very sensitive but not very specific: therefore, they do not lead to 100% accuracy.

Although very useful to detect intraepidermal lesions, dermoscopy is limited in regard to nodular lesions or clearly dermal lesions, lesions without pigmentation, very dark lesions in which the amount of pigment does not allow the observation of ELM signs, and faintly pigmented seborrheic warts.
A recent meta-analysis has provided more evidence that clinical examination with the use of dermoscopy is more accurate than naked eye examination alone for discriminating melanoma from non-melanoma in suspicious skin lesions for clinicians with at least minimal training in dermoscopy [9].

The adoption of dermoscopy in routine melanoma screening improves the malignant-benign ratio in excised lesions (from 1:18 to 1:4.3, P = 0.037). Furthermore dermoscopy may be cost saving, by reducing the false-positive diagnosis (and consequently the excision rate of benign lesions) [28].
However the efficiency of dermoscopy is closely related to an integrated diagnostic synopsis for trained clinicians [30,31].

The user must think in global diagnostic terms when considering the accuracy of dermoscopy findings, independent of the methods used; a broader aim is to include case histories and clinical assessment.
In fact, the first steps to be integrated by dermoscopic evaluation should be as follows:

1) Anamnesis (personal and family background)
2) Photo-type
3) Previous sunburn history
4) Complete analysis of the entire skin surface

Such a combination of the traditional clinical diagnostic procedures and dermoscopy allows better classification of melanocytic lesions [30,31].


12. Amelanotic melanoma

Amelanotic malignant melanoma is a subtype of cutaneous melanoma with little or no pigment at visual inspection [17,30,33]. Amelanotic melanomas represent 2-8% of all malignant melanomas; the precise incidence is difficult to calculate because the term amelanotic is often used to indicate melanomas only partially devoid of pigment.
Truly amelanotic melanomas are rare; often some pigmentation is present at the periphery of the lesion, and they may mimic benign and malignant variants of both melanocytic and non-melanocytic lesions.

According to the extent of the hypopigmentation, amelanotic melanoma can be classified as follows:
A) truly amelanotic melanoma, lacking any trace of melanin even if viewed under dermoscopy;
B) partially pigmented melanoma, with larger or smaller pigmented sections covering up to 30% of its total surface;
C) hypomelanotic melanoma, showing a faint brownish tan with little variation of its intensity, which can occupy more than 30% of its total surface and may cover the entire area.

Amelanotic malignant melanoma tends to occur in sun-exposed skin, especially in elderly persons with photodamage, and may appear as erythematous, sometimes scaly, macules or plaques with irregular borders, simulating benign inflammatory plaques, superficial basal cell carcinoma, actinic keratosis, Paget disease, or Bowen disease.
It may also manifest as translucent papules, thereby resembling basal cell carcinoma, or it may clinically resemble keratoacanthoma or Merkel cell carcinoma. Alternatively, it may manifest as an exophytic nodule, often eroded, simulating a pyogenic granuloma or hemangioma, or as a skin-colored dermal plaque/nodule known as desmoplastic malignant melanoma.

From a dermoscopic point of view, amelanotic melanoma lacks most of the dermoscopic criteria reflecting pigmentation, and the vascular structures are frequently the only clue for its diagnosis. The vascular patterns associated to amelanotic melanoma include milky-red globules/areas of dotted or linear irregular or polymorphous vessels (ie, a combination of dotted and linear irregular vessels (FIGURE 59). In addition, irregular hairpin-like or glomerular vessels can also be found in amelanotic melanoma, albeit less frequently.

Because dermoscopy uses criteria reflecting pigmentation and vascular patterns, it is a useful technique for pigmented melanoma and for amelanotic melanoma. However, the vascular patterns can suggest a diagnosis of melanoma when associated with other criteria found in melanocytic lesions, such as pigment network, irregular pigmentation, streaks, irregular dots/globules, regression structures, and a blue-whitish veil.
In truly amelanotic melanoma, vascular patterns alone may not be sufficient to diagnose melanoma because hairpin vessels, dotted areas, and even milky-red areas have also been found in seborrheic keratosis and common nevi, respectively, and in melanomas.

A combined approach of dermoscopic evaluation and clinical examination including clinical information such as age, sex, history of melanoma and/or of excessive sun exposure, number and sites of lesions, time of onset, and descriptions of any changes of the lesion over time must play an important role in the diagnosis of truly amelanotic melanoma and for the so-called "featureless" melanomas that lack specific surface microscopic features.


FIGURE 59: Amelanotic melanoma: vascular pattern associated to amelanotic melanoma: combination of dotted vessels (°) and linear irregular vessels (*).




13. Difficult diagnosis

The primary goal of melanoma detection is early tumor recognition and subsequent surgical treatment. The ABCD method for detecting cutaneous melanoma has been a useful tool in distinguishing benign lesions from melanoma. However, the clinical diagnosis of cutaneous melanoma may be difficult because some melanomas lack all or most of the features of the "ABCD" rule. In fact, some authors [29-31] have identified a subset of melanomas of unusual appearance, clinically indistinguishable from other pigmented and non-pigmented cutaneous lesions, that escape clinical recognition: the most common clinical diagnoses of these histopathologically confirmed melanomas were nevus, basal cell carcinoma, seborrheic keratosis, and lentigo, while the less common diagnoses included Bowen disease, verruca vulgaris, dermatofibroma, pyogenic granuloma, and hemangioma.

Dermoscopic diagnosis for melanoma also may be difficult because some cases lack specific features for melanoma. Some authors have demonstrated the limitations of dermoscopy in the detection of early melanomas that present with an uncharacteristic dermoscopic appearance. Some melanomas, the so-called "featureless melanomas," may lack specific dermoscopic features for melanoma diagnosis and dermoscopically may even appear as benign melanocytic lesions (nevus-like melanomas) or as atypical nevi, so that the diagnosis is impossible to make on dermoscopic grounds alone [22,30,31].
In fact, difficult melanomas present dermoscopic patterns indistinguishable from those of atypical nevi and common nevi. According some authors, melanomas that failed dermoscopic detection belong to the 3 following categories: melanomas showing criteria of melanocytic nevi, melanomas exhibiting criteria of non-melanocytic lesions, and melanomas lacking specific criteria of a melanocytic or non-melanocytic lesion (hypomelanotic/amelanotic melanoma) [22,30,31].
In addition, dermoscopy does not solve the dilemma of discriminating early, featureless melanoma from dysplastic nevi.
Only a meticulous comparative and interactive process based on an assessment of all the individual’s nevi ("ugly ducking" sign) and a knowledge about recent changes can lead to the recognition of melanomas that are difficult to diagnose [30].


14. References

1. Del Mar C, Green A, Cooney T et al. Melanocytic lesions excised from the skin: what percentage are malignant? Aust. J Public Health 1994, 18:221-3.

2. Miller M, Ackermann AB. How accurate are dermatologists in the diagnosis of melanoma? Degree of accuracy and implication. Arch Dermatol 1992, 128:559-560.

3. Pehamberger H., Steiner A., Wolff. K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987, 17: 571-83.

4. Pehamberger H, Binder M, Steiner A et al. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993, 100:356S-362S.

5. Massone C, Di Stefani A, Soyer P. Dermoscopy for skin cancer detection. Curr Opin Oncol 2005; 17:147–153.

6. Soyer HP, Smolle J, Hodl S et al. Surface microscopy: a new approach to the diagnosis of cutaneous pigmented tumors. Am J Dermatopathol 1989;11:1–10.

7. Yadav S, Vossaert KA, Kopf AW et al. Histopathologic correlates of structures seen on dermoscopy (epiluminescence microscopy). Am J Dermatopathol 1993;15:297–305.

8. Kittler K, Pehamberger H, Wolff et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159-165.

9. Vestergaard ME, Macaskill P, Holt PE et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting Brit J Dermatol 2008 159:669–676.

10. Epstein E. Instrumentation for epiluminescence microscopy: the gap between research and practice. Arch Dermatol 1996; 132: 91-2.

11. Wolff K. Instrumentation for epiluminescence microscopy: the gap between research and practice (reply). Arch Dermatol 1996; 132: 92.

12. Pellacani G, Seidenari S. Comparison between morphological parameters in pigmented skin images acquired by means of epiluminescence surface microscopy and polarized-light videomicroscopy. Clin Dermatol 2002; 20:222-227.

13. Andrade CB, Dusza SW, Agero ALC et al. Differences between polarized light dermoscopy and immersion contact dermoscopy for the evaluation of skin lesions. Arch Dermatol 2007;143:329-338.

14. Massone C, Hofmann-Wellenhof R, Ahlgrimm-Siess V et el. Melanoma screening with cellular phones PLoS ONE 2007 30;2:e483

15. Stanganelli L, Bucchi L. Dermatology and Venereology Society of the Canton of Ticino. Epiluminescence microscopy versus clinical evaluation of pigmented skin lesions: Effects of operator's training on Reproducibility and Accuracy. Dermatology 1998; 196:199-203.

16. Stanganelli I, Burroni M, Rafanelli S et al. Intraobserver agreement in the interpretation of digital epiluminescence microscopy. J Am Acad Dermatol 1995; 33: 584-589.

17. Kreusch J, Koch F. Auflichtmikroskopische Charakterisierung von Gefassmustern in Hauttumoren. Hautarzt 1996;47:264–72.

18. Peris K, Ferrari A, Argenziano G et al. Dermoscopic classification of Spitz/Reed nevi. Clin Dermatol 2002; 20:259-62.

19. Hakasu R, Sugiyama H, Arali M et al.. Dermatoscopic and videomicroscopic features of melanocytic plantar nevi. Am J Dermaopathol 1997: 18:10-18.

20. Argenziano G; Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions: Results of a Consensus Meeting via the internet. JAAD 2003;48:679-93.

21. Argenziano G, Fabbrocini, Carli P et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998, 134:1563-70.

22. Menzies SW, Ingvar C, Crotty KA et al. Frequency and morphologic characteristics of invasive melanoma lacking specific surface microscopy features. Arch Dermatol 1996; 132: 1178-82.

23. Stolz W, Riemann A, Armand B et al. ABCD rule of dermoscopy: a new practical method for early recognition of melanoma. Eur J Dermatol 1994.

24. Kenet RO, Fitzpatrick TB. Reducing mortality and morbility of cutaneous melanoma: a six years plan. B) Identifying high and low risk pigmented lesions using epiluminescence microscopy. J Dermatol 1994; 21: 881-884.

25. Ascierto PA, Palmieri G, Botti G et al. Early diagnosis of malignant melanoma: proposal of a working formulation for the management of cutaneous pigmented lesions from the melanoma cooperative group. Int J Oncol 2003, 22:1209-1215.

26. Henning JS, Dusza SW, Wang SQ et al. The CASH (color, architecture,symmetry, and homogeneity algoritm for dermoscopy. J Am Acad Dermatol 2007 Jan;56(1):45-52.

27.Carli P. De Giorgi V, Giannotti B. Dermoscopy and Early Diagnosis of Melanoma. The light and the dark (editorial). Arch Dermatol 2001, 137:1641-4.

28. Carli P, De Giorgi V, Crocetti E et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the ‘dermoscopy era’: a retrospective study 1997-2001. Br J Dermatol 2004; 150:687-692.

29. Carli P, De Giorgi V, Giannotti B. Dermoscopy as a second step in the diagnosis of doubtful pigmented skin lesions: how great is the risk of missing a melanoma. JEADV 2001; 15:24-26.

30. Pizzichetta MA, Stanganelli I, Bono R et al. Dermoscopic features of difficult melanoma. Dermatol Surg 2007, 33:91-9.

31. Puig S, Argenziano G, Zalaudek I et al. Melanomas that failed dermoscopic detection: a combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg 2007, 33:1262-73.

32. Pizzichetta MA, Talamini R, Stanganelli I et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol 2004, 150:1117-24.

33. Argenziano G, Zalaudek I, Corona R et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004 Dec;140(12):1485-9.



Author(s)

Ignazio Stanganelli, MD - Skin Cancer Unit, IRST, Meldola, and Ospedale Niguarda, Milan, Italy.

Updated

October 2008



Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

JARID1B POSITIVE MELANOMA CELLS
Using the H3K4 demethylase JARID1B as biomarker, investigators have characterized a small subpopulation of slow-cycling melanoma cells required for continuous tumor growth.
Source: Roesch A, Cell 2010, 141:583-94.

NUCLEOTIDE EXCISION REPAIR
Melanoma cells retain capacity for nucleotide excision repair (NER), the loss of which probably does not commonly contribute to melanoma progression.
Source: Gaddameedhi S, Cancer Res 2010, 70:4922-30.

MELANOMA DORMANCY
In a mouse melanoma model, Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, reinforcing the theory that immune responses favor dormancy of disseminated tumor cells.
Source: Eyles J, J Clin Invest 2010, 120:2030-9.

MTAP AND INTERFERON
Expression of methylthioadenosine phosphorylase (MTAP) might represent a predictive marker for response to adjuvant interferon therapy in patients with skin melanoma.
Source: Meyer S, Exp Dermatol 2010, 19:e251-7.

TARGETING RAP1 GTPase
Preventing the activation or cycling of the Rap1 GTPase alters adhesion and cytoskeletal dynamics and blocks metastatic melanoma cell extravasation into the lungs.
Source: Freeman SA, Cancer Res 2010, 70:4590-601.

FOLLOW-UP FOR STAGE III MELANOMA
Based on the analysis of retrospective data, investigators suggest new guidelines for the follow up of patients with stage III melanoma.
Source: Romano E, J Clin Oncol 2010, 28:3042-7.

ANTI-BPAG1 AUTO-ANTIBODY
Serum levels of anti-BPAG1 auto-antibodies are higher in melanoma patients than in healthy volunteers and thus are proposed as novel melanoma diagnostic marker.
Source: Shimbo T, PLoS One 2010, 5:e10566.

SHIELDS PROGNOSTIC INDEX
The Shields index, a non-invasive analysis based on immunohistochemistry of lymphatics surrounding primary lesions, is proposed to predict outcome of melanoma patients.
Source: Emmett MS, BMC Cancer 2010, 10:208.

PLK1 INHIBITOR BI-2536
In a phase II trial of polo-like kinase 1 inhibitor BI 2536, no objective tumor response was observed in patients with different types of metastatic cancer, including melanoma.
Source: Schoffski P, Eur J Cancer 2010, 46:2206-15.

TOPOISOMERASE I AMPLIFICATION
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
Source: Ryan D, Pigment Cell Melanoma Res 2010, 23:542-53.

NOVEL SMAC MIMETICS
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Source: Lecis D, Br J Cancer 2010, 102:1707-16.

CHIMERIC ANTIGEN RECEPTORS (CAR)
Designer T cells with second generation GD3-specific CAR plus systemic interleukin-2 (IL2) can eradicate subcutaneous established GD3+ melanoma in nude mice.
Source: Lo AS, Clin Cancer Res 2010, 16:2769-80.

APREPITANT
The NK-1 receptor is expressed by human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on human melanoma cell lines.
Source: Munoz M, Lab Invest 2010, 90:1259-69.

BEVACIZUMAB + IFNalpha
In a pilot trial, patients with metastatic ocular melanoma were treated with bevacizumab and IFN-alpha, which were well tolerated and showed some clinical activity.
Source: Guenterberg KD, Am J Clin Oncol 2010, Epub ahead of print.

GITR ACTIVATION
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell (Treg) stability and intra-tumor accumulation.
Source: Cohen AD, PLoS One 2010, 5:e10436.

ETARACIZUMAB
The findings of a pharmacodynamic (phase 0) study using etaracizumab (a monoclonal antibody targeting integrin alpha V beta3) in advanced melanoma have been reported.
Source: Moschos S, J Immunother 2010, 33:316-25.

CD147 SILENCING
Depletion of CD147 (a cell surface receptor for cyclophilin A) sensitizes human malignant melanoma cells to hydrogen peroxide-induced oxidative stress.
Source: Li J, J Dermatol Sci 2010, 58:204-10.

9.2.27PE IMMUNOTOXIN
9.2.27PE (Pseudomonas Exotoxin A) immunotoxin can efficiently cause cell death in malignant melanoma cells independent of their level of resistance to apoptosis and DTIC.
Source: Risberg K, J Immunother 2010, 33:272-8.

TARGETED INTERNAL RADIONUCLIDE THERAPY
Melanin targeting radionuclide therapy with a quinoxaline-derived molecule (ICF01012) has strong anti-tumoral efficacy in pigmented versus unpigmented melanomas.
Source: Bonnet M, Pigment Cell Melanoma Res 2010, Epub ahead of print

NRASQ61R and CRE-RECOMBINASE
Targeted delivery of mutationally activated NRAS (NRASQ61R) and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
Source: VanBrocklin MW, Pigment Cell Melanoma Res 2010, 23:531-41

microRNA DEREGULATED IN MELANOMA
miRNA-200c is consistently downregulated in melanocytes, melanoma cell lines and patient samples, whereas miRNA-205 and miRNA-23b are markedly reduced only in patient samples. miR-146a and miR-155 are upregulated in all analyzed patients but none of the cell lines.
Source: Philippidou D, Cancer Res 2010, 70:4163-73

131-I-LABELED BENZAMIDE
In a xenograft model, 131-I-labeled benzamide proved to be effective for targeted radiotherapy of human melanoma.
Source: Joyal JL, Cancer Res 2010, 70:4045-53

MIC-1 AND ANGIOGENESIS
Inhibition of macrophage inhibitory cytokine 1 (MIC-1) retards melanoma tumor vascular development, subsequently affecting tumor cell proliferation and apoptosis.
Source: Huh SJ, Am J Pathol 2010, 176:2948-57

3-BROMOPYRUVATE
3-bromopyruvate (BrPA) - an inhibitor of glucose metabolism - selectively kills melanoma cells with low levels of glutathione.
Source: Qin JZ, Biochem Biophys Res Commun 2010, 396:495-500

c-RET AND GDNF
Constitutively activated RET-carrying transgenic mice (RET-mice) spontaneously develop malignant melanoma and glial cell line-derived neurotrophic factor (GDNF)-mediated c-RET kinase activation is associated with melanoma pathogenesis.
Source: Ohshima Y, PLoS One 2010, 5:e10279

IGF1R INHIBITION
Disruption of insulin-like growth factor 1 receptot (IGF1R) signaling increases TRAIL-induced apoptosis in human melanoma cell lines.
Source: Karasic TB, Exp Cell Res 2010, 316:1994-2007

IL-24 AND ERLOTINIB
Interleukin-24 (IL-24) gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
Source: Deng WG, Melanoma Res 2010, Epub ahead of print

PROTEIN KINASE C ALPHA
RNA interference (RNAi)-mediated knockdown of protein kinase C-alpha (PKC-alpha) inhibits cell migration in MM-RU human metastatic melanoma cell line.
Source: Byers HR, Melanoma Res 2010, 20:171-8

NITRIC OXIDE SYNTHASE INHIBITION
Targeted inhibition of inducible nitric oxide synthase (iNOS)inhibits growth of human melanoma in vivo and synergizes with chemotherapy.
Source: Sikora AG, Clin Cancer Res 2010, 16:1834-44

CXCL4L1/PF-4var47-70
The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
Source: Vandercappellen J, Mol Cancer Res 2010, 8:322-34

FOXP3
Intratumoral forkhead box P3-positive regulatory T (Treg) cells predict poor survival in cyclooxygenase-2 (COX2) positive uveal melanoma.
Source: Mougiakakos D, Cancer 2010, 116:2224-33

TRIB2
Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.
Source: Zanella F, Oncogene 2010, 29:2973-82

IPILIMUMAB IMPROVES SURVIVAL
In a phase III RCT, anti-CTLA4 antibody ipilimumab (combined or not with gp100 vacination) significantly improves the survival of patients with advanced melanoma resistant to conventional chemotherapy (as compared to gp100 vaccination).
Source: Hodi FS, N Engl J Med 2010, Epub ahead of print

MELANOMA INITIATING CELLS AND CD271
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
Source: Boiko AD, Nature 2010, 466:133-7

RCT OF THYMOSIN ALPHA 1
In a phase III RCT, thymosin increases tumor response rates but not overall survival as compared to DTIC + interferon (IFN) alpha.
Source: Maio M, J Clin Oncol 2010, 28:1780-7

LEPTIN AND MELANOMA GROWTH
The metabolic hormone leptin is a melanoma growth factor: a leptin-based autocrine loop may contribute to the proliferation of melanoma cells.
Source: Ellerhorst JA, Oncol Rep 2010, 23:901-7

IGFBP7 GENE THERAPY
Intratumoral injection of pEGFC1-IGFBP7 inhibits malignant melanoma growth in C57BL/6J mice by inducing apoptosis and downregulating VEGF expression.
Source: Chen RY, Oncol Rep 2010, 23:981-8

B-CELLS AND ANTI-MELANOMA IMMUNITY
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.
Source: DiLillo DJ, J Immunol 2010, 184:4006-16

PD-1 BLOCKADE + COMBINED IMMUNOTHERAPY
Blockade of programmed death ligand 1 (PD-1) enhances the therapeutic efficacy of combination immunotherapy against murine melanoma in vivo.
Source: Pilon-Thomas S, J Immunol 2010, 184:3442-9

BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY
Using both a murine model and patient biopsies, investigators suggest that resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in melanoma.
Source: Helfrich I, J Exp Med 2010, 207:491-503

MC1R VARIANTS AND CDKN2A MUTATIONS
In a meta-analysis of the literature, MC1R variants significantly increase the penetrance of CDKN2A mutations in melanoma-prone families.
Source: Fargnoli MC, Eur J Cancer 2010, 46:1413-20

IL-24 PLUS DTIC
In a human in vitro model, the combination of interleukin-24 gene therapy and dacarbazine showed anti-melanoma synergism.
Source: Jiang G, Cancer Lett 2010, Epub ahead of print

CONDITIONAL SURVIVAL ANALYSIS (CSA)
Using the SEER database (n=8,647), investigators found that - 8 years after primary surgery - survival differences between low (T2-3N0M0) and high (T4N0M0 or T2-4N1-3M0) risk melanoma patients are no longer significant.
Source: Rueth NM, Ann Surg Oncol 2010, Epub ahead of print

PLEXIN-B1: MELANOMA SUPPRESSOR GENE ?
Plexin B1 can act as a tumor-suppressor protein in melanoma, in part through suppression of c-MET signaling: however, since it also activates AKT, plexin B1 may function as a tumor promoter in melanomas not driven by c-MET activation.
Source: Stevens L, J Invest Dermatol 2010, Epub ahead of print

PESTICIDES AND MELANOMA RISK
In the Agricultural Health Study cohort of licensed pesticide applicators, some pesticides were significantly associated with increased melanoma risk.
Source: Dennis LK, Environ Health Perspect 2010, Epub ahead of print

MITF-MDEL: NEW MELANOMA BIOMARKER
MITF-Mdel, a novel melanocyte/melanoma-specific isoform (splice variant) of microphthalmia-associated transcription factor-M, is proposed as a candidate biomarker for melanoma.
Source: Wang Y, BMC Med 2010, 8:14

4-METHYLUMBELLIFERONE (4-MU)
4-MU inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors.
Source: Edward M, Br J Dermatol 2010, Epub ahead of print

PD1 AND CTLA4 BLOCKADE
PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T-cells (Treg) and myeloid suppressor cells within B16 melanoma tumors.
Source: Curran MA, Proc Natl Acad Sci USA 2010, 107:4275-80

ETV1: NEW MELANOMA ONCOGENE
ETV1 in combination with oncogenic NRAS(G12D) transformed primary melanocytes (which was dependent on MITF overexpression) and promoted tumor formation in mice.
Source: Jané-Valbuena J, Cancer Res 2010, 70:2075-84

IGFBP7 GENE THERAPY
In vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downregulation.
Source: Chen RY, J Exp Clin Cancer Res 2010, 29:13

SELENIUM ANTI-MELANOMA ACTIVITY
In a mouse model, selenium inhibits melanoma metastasis through the induction of cell cycle arrest and cell death.
Source: Song H, Immune Netw 2009, 9:236-42

OCCULT NODAL METASTASIS
In a large series of patients with thin melanoma (n=1732), a scoring system and nomogram for the risk of nodal involvement was created using 3 variables: sex, age and Breslow tumor thickness.
Source: Faries MB, Arch Surg 2010, 145:137-42

CD4+ CYTOTOXIC T-CELLS
Tumor-reactive CD4(+) T-cells - especially in association with anti-CTLA4 antibody - develop cytotoxic activity and eradicate large established syngeneic melanoma after transfer into lymphopenic hosts.
Source: Quezada SA, J Exp Med 2010, 207:637-50

TRICHOSTATIN PLUS 5-AZA
Histone deacetylase inhibitor (HDACI) trichostatin A (TSA) and the DNA methyltransferase inhibitor (DNMTI) 5-azacytidine (5-AZA) show synergistic anti-melanoma activity in vitro.
Source: Essa S, J Steroid Biochem Mol Biol 2010, Epub ahead of print

S100B SERUM LEVELS
Elevated serum levels of protein S100B during the follow-up of patients with melanoma (n=46) showed a low positive predictive value (50%) for disease recurrence.
Source: Aukema TS, Ann Surg Oncol 2010, Epub ahead of print

NEW PROBE FOR PET
In a preclinical in vivo model, (18)F-MEL050 - a melanin selective compound - showed to perform better than standard (18)F-FDG as a PET probe.
Source: Denoyer D, J Nucl Med 2010, 51:441-7

IMIDAZOLE DERIVATIVE 7A
In a human in vitro model, pyrimidin-4-yl-1H-imidazole derivative 7a showed greater anti-melanoma activity than sorafenib and turned out to be a strong CRAF inhibitor.
Source: Lee J, Bioorg Med Chem Lett 2010, 20:1573-7

PLX4032: BRAF V600E SELECTIVE INHIBITOR
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Source: Halaban R, Pigment Cell Melanoma Res 2010, 23:190-200

NOW AVAILABLE: TARGETED THERAPY DATABASE
The MMMP website now hosts a new database coupled with an original model to match the patient's molecular profile with the available evidence on melanoma targeted therapy (drug ranking system).
Source: MMMP_Targeted Therapy Database

FIRST HUMAN EXPERIENCE OF siRNA + TARGETED NANOPARTICLES
The first phase I clinical trial involving the systemic administration of small interfering RNA (siRNA) to patients with solid cancers using targeted nanoparticles is ongoing. Evidence of inducing RNA intereference in a patient with melanoma has been provided.
Source: Davis ME, Nature 2010, Epub ahead of print

RESPONSE TO IPILIMUMAB
In a multicenter single-arm phase II trial of ipilimumab (monotherapy) for pretreated advanced melanoma (n=155), the best overall response rate was 5.8% and the disease control rate was 27%.
Source: O'Day SJ, Ann Oncol 2010, Epub ahead of print

GENOME-WIDE METHYLATION PROFILING
Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene upregulation in melanoma.
Source: Rubinstein JC, BMC Med Genomics 2010, 3:4

PD1 LIGAND AND PROGNOSIS
Tumor cell expression of programmed cell death-1 (PD1) ligand is an independent prognostic factor for patients with melanoma (n=59).
Source: Hino R, Cancer 2010, 116:1757-66

IPILIMUMAB AND LYMPHOCYTE COUNT
Absolute lymphocyte count determined in the peripheral blood after 2 cycles of ipilimumab correlates with improved survival of patients with advanced melanoma (n=53).
Source: Ku GY, Cancer 2010, 116:1767-75

POPULATION ATTRIBUTABLE FRACTION (PAF)-2
In a meta-analysis of 66 studies, the PAF for people with skin phototypes I/II, presence of freckling and blond hair color were 27%, 23% and 23%, respectively.
Source: Olsen CM, Int J Cancer 2010, Epub ahead of print

IFN-GAMMA + GGTI298
Human melanoma cells treated with IFN-gamma and geranylgeranyl transferase inhibitor GGTI-298 enhance generation and activity of melanoma-specific cytotoxic T cells.
Source: Sarrabayrouse G, PLoS One 2010, 5:e9043

SLN STATUS "S" CLASSIFICATION
The "S" classification of the SLN status accurately predicts the status of non-sentinel nodes in a series of 365 patients.
Source: Younan R, Ann Surg Oncol 2010, Epub ahead of print

RIBOSOME INHIBITING PROTEIN (RIP)
In a xenograft model, single chain RIP (derived from Shiga like toxin, SLT) synergically increases the therapeutic potential of DTIC.
Source: Cheung MC, Mol Cancer 2010, 9:28

INTEGRIN ALPHA 4
In a murine model, expression of integrin alpha 4 (ligand for endothelial VCAM1) correlates with lymph node metastasis rate.
Source: Rebhun RB, Neoplasia 2010, 12:173-82

PACLITAXEL + CELECOXIB
In a phase II trial (n=20), metronomic paclitaxel + celecoxib (COX2 inhibitor) yielded one partial response and three disease stabilizations.
Source: Bhatt RS, Cancer 2010, 116:1751-6

RCT OF ETARACIZUMAB
In a phase II RCT, dacarbazine does not add significant therapeutic benefit to etaracizumab (a monoclonal antibody against integrin alpha V beta 3.
Source: Hersey P, Cancer 2010, 116:1526-1534

SNB IN 1-2 MM THICK MELANOMA
In a large series of patients (n=1110), sentinel node metastasis was found in 133 cases (12%) and sentinel node status independently predicted survival.
Source: Mays MP, Cancer 2010, 116:1535-44

INTERLEUKIN-29 (IL-29)
IL-29 (interferon lambda 1) binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Source: Guenterberg KD, Mol Cancer Ther 2010, 9:510-20

SPARC SILENCING
In a xenograft model, SPARC silencing shows therapeutic effects against human melanoma.
Source: Horie K, Cancer Sci 2009, Epub ahead of print

IXABEPILONE PHASE II TRIAL
This epotilone B analogue has no therapeutic activity in patients (n=23) with metastatic melanoma.
Source: Ott PA, PLoS One 2010, 5:e8714

MMP-19 AND INVASIVENESS
Matrix metalloproteinase 19 (MMP-19) is upregulated during melanoma progression and increases invasion of human melanoma cells in vitro.
Source: Muller M, Mod Pathol 2010, Epub ahead of print

BEVACIZUMAB FOR OCULAR MELANOMA
In a xenograft model of uveal melanoma, the anti-VEGF antibody bevacizumab suppressed hepatic micrometastasis.
Source: Yang H, Invest Ophthalmol Vis Sci 2010, Epub ahead of print

SLN TUMOR BURDEN
In a series of 381 patients who underwent SLN biopsy, patients with SLN metastatic deposits less or =0.2 mm had no additional positive non-SLN and no recurrences or deaths were recorded.
Source: Francischetto T, Ann Surg Oncol 2010, 17:1152-8

DIAGNOSTIC HELP FROM FISH
Fluorescence in situ hybridization (FISH) is a useful adjunct tool to traditional methods in the diagnostic workup of deposits of melanocytes in lymph nodes that are histopathologically ambiguous .
Source: Dalton SR, Am J Surg Pathol 2010, 34:231-7

POPULATION ATTRIBUTABLE FRACTION (PAF)-1
In a meta-analysis of 49 studies, the PAF for people with > or =1 atypical nevi was 25% and for people with > or =25 common nevi was 42%.
Source: Olsen CM, Cancer Prev Res 2010, 3:233-45

TREMELIMUMAB PHASE II TRIAL
In this trial (n=251), tremelimumab showed an objective response rate of 6.6%, with all responses being durable > or =170 days.
Source: Kirkwood JM, Clin Cancer Res 2010, 16:1042-8

SWI/SNF COMPLEX
SWI/SNF chromatin remodeling complex is critical for the expression of MITF and could represent a novel therapeutic target.
Source: Vachtenheim J, Biochem Biophys Res Commun 2010, 392:454-9

IPILIMUMAB + DACARBAZINE
In a phase II trial (n=72), anti-CTLA4 antibody ipilimumab + DTIC yielded a 14.3% tumor response rate in patients with advanced melanoma (ipilimumab alone: 5.4%).
Source: Hersh EM, Invest New Drugs 2010, Epub ahead of print

NEOADJUVANT TEMOZOLOMIDE
In a phase II trial (n=19), neaodjuvant TMZ yielded 16% tumor response rate (similar to metastatic setting), independently of the MGMT promoter methylation status.
Source: Shah GD, Ann Oncol 2010, Epub ahead of print

TEMOZOLOMIDE + CISPLATIN
In a phase II trial (n=30), chemonaive patients treated with TMZ + CDDP showed high toxicity and no apparent benefit, tumor response being similar to single-agent therapy.
Source: Wierzbicka-Hainaut E, Melanoma Res 2010, 20:141-6

CYSTATIN E/M AND LEGUMAIN
In an in vitro model, human melanoma cells forced to express the cystein protease inhibitor cystatin E/M show decreased levels of legumain and reduced invasiveness.
Source: Briggs JJ, BMC Cancer 2010, 10:17

MELANOMA DORMANCY
In a German population of patients with TNM stage I-II melanoma (n=1881), 20 cases (1.1%) of late (> 10 years) recurrences were recorded.
Source: Hansel G, J Eur Acad Dermatol Venereol 2010, Epub ahead of print

MELANOMA STEM CELLS AND IMMUNITY
ABCB5+ melanoma initiating cells can increase the number of immunosuppressive T regulatory (Treg) cells.
Source: Schatton T, Cancer Res 2010, 70:697-708

MELAPRO AND RISK COUNSELING
MelaPRO is an algorithm that provides germline CDKN2A mutation probabilities and melanoma risk to individuals from melanoma-prone families; it seems to outperform the existing predictive model MELPREDICT.
Source: Wang W, Cancer Res 2010, 70:552-9

p21/WAF1/CIP1 AND MITF
Cell cycle inhibitor p21 stimulates MITF expression, which in turn enhances p21 expression: this might explain the tolerance of increased p21 levels found in some melanomas.
Source: Sestáková B, Pigment Cell Melanoma Res 2010, Epub ahead of print

PAX3, SOX10 AND MET
PAX3 and SOX10 activate expression of MET, which in turn promotes melanoma migration, invasion, resistance to apoptosis and cell growth.
Source: Mascarenhas JB, Pigment Cell Melanoma Res 2010, Epub ahead of print

NOTCH1 AND MELANOMA DEVELOPMENT
Active Notch1 confers a transformed phenotype to primary human melanocytes.
Source: Pinnix CC, Cancer Res 2009, 69:5312-20

NRG1/ERBB3 SIGNALING
NRG1/ERBB3 signaling plays an important role in melanocyte development and melanoma by inhibiting differentiation and promoting proliferation.
Source: Buac K, Pigment Cell Melanoma Res 2009, 22:773-84

MELANOMA SOMATIC MUTATIONS
A comprehensive catalogue of somatic mutations from a human melanoma genome has been published.
Source: Pleasance ED, Nature 2010, 463:191-6

FAMILIAL MELANOMA: ATTRIBUTABLE RISK
A meta-analysis shows that only a small percentage of melanoma cases (always less than 7%) are attributable to familial risk.
Source: Olsen CM, Cancer Epidemiol Biomarkers Prev 2010, 19:65-73

HIF1-ALPHA AND PROGNOSIS
Expression of hypoxia inducible factor 1 alpha is not associated with survival of patients (n=89) with cutaneous melanoma.
Source: Valencak J, Clin Exp Dermatol 2009, 34:e962-4

MARCO AND DENDRITIC CELLS
In a murine melanoma model, targeting MARCO (a novel member of the cell surface class A scavenger receptor family) leads to enhanced DC motility and anti-melanoma activity.
Source: Matsushita N, Cancer Immunol Immunother 2010, Epub ahead of print

LOW DOSE IFN: 18 VS 60 MONTHS
In a phase III RCT (n=850), low dose IFN alpha administered for 18 or 60 months yielded no different results in terms of survival.
Source: Hauschild A, J Clin Oncol 2010, 28:841-6

NEW MODEL FOR DE NOVO MELANOMA
A de novo melanoma model in RET mice that are heterozygous for Ednrb has been developed and suggests that reduced expression of Ednrb might facilitate melanoma development.
Source: Kumasaka MY, Cancer Res 2010, 70:24-9

MELANOMA PROPAGATING CELLS (MPC)
Tumor formation capability decreases for CD34+/p75-, CD34-/p75- and CD34-/p75+ melanoma cells, respectively. MPC are chemoresistant as compared to non-MPC.
Source: Held MA, Cancer Res 2010, 70:388-97

VITAMIN D RECEPTOR POLYMORPHISMS
Vitamin D receptor (VDR) polymorphisms are associated with both melanoma risk and progression.
Source: Halsall JA, Dermatoendocrinol 2009, 1:54-7

METHIONINE FREE DIET + CYSTEMUSTINE
In a phase II trial (n=20), this regimen led to a median survival of 4.6 months, with 2 long-duration stabilizations.
Source: Thivat E, Anticancer Res 2009, 29:5235-40

PLP2 AND MELANOMA METASTASIS
Forced expression of phospholipid protein 2 (PLP2) enhanced melanoma proliferation, adhesion and invasion in vitro and tumor metastasis in vivo.
Source: Sonoda Y, Oncol Rep 2010, 23:371-6

GENE SIGNATURE OF INVASIVENESS
Global transcript profiling identified a signature featuring decreased expression of developmental and lineage specification genes (MITF, EDNRB, DCT, TYR) and increased expression of genes involved in interaction with the extracellular environment (PLAUR, VCAN, HIF1-alpha).
Source: Jeffs AR, PLoS One 2009, 4:e8461

POLY-EPITOPE VACCINE
Poly-epitope vaccination yielded high rates of immunological responses but only one partial response and five disease stabilizations in 41 patients with advanced melanoma.
Source: Dangoor A, Cancer Immunol Immunother 2009 Epub ahead of print

ROLE OF INFLAMMASOME
An in vitro model suggests that IL-1-mediated autoinflammation contributes to development and progression of human melanoma.
Source: Okamoto M, J Biol Chem 2010, 285:6477-88

ABCA1 AND CURCUMIN RESISTANCE
Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells (ABCA1 should be considered as response marker).
Source: Bachmeier BE, Mol Cancer 2009, 8:129

HISTOLOGICAL REGRESSION AND SN STATUS
Primary melanoma histological regression is not an independent predictor of sentinel node (SN) status in a cohort of 397 patients.
Source: Socrier Y, Br J Dermatol 2009, Epub ahead of print

BORTEZOMIB + TEMOZOLOMIDE
In a phase I trial of bortezomib + temozolomide (n=19) the investigators defined the doses for phase II trials; one partial response and 4 disease stabilizations were observed.
Source: Su Y, Clin Cancer Res 2010, 16:348-57

E2F1 AND MELANOMA METASTASIS
In a xenograft model, inhibition of E2F1 expression (which targets EGFR expression) via small hairpin RNA (shRNA) shows anti-melanoma potential in vivo.
Source: Alla V, J Natl Cancer Inst 2010, 102:127-33

ELAFIN ANTI-MELANOMA ACTIVITY
In a xenograft model, protease inhibitor elafin shows anti-melanoma potential in vivo.
Source: Yu KS, Int J Cancer 2009, Epub ahead of print

SYNERGISM LBW242 + TLR3 LIGAND
In an in vitro model, SMAC mimetic LBW242 synergizes with TLR3 ligand Poly I:C to induce apoptosis of human melanoma cells.
Source: Weber A, Cell Death Differ 2009, Epub ahead of print

IPILIMUMAB PHASE II TRIAL
In a phase II dose-ranging trial (n=217) of this anti-CTLA4 antibody for metastatic melanoma, the best overall response rate was 11.1% for 10 mg/kg, 4.2% for 3 mg/kg, and 0% for 0.3 mg/kg (trend test P=0.0015).
Source: Wolchok JD, Lancet Oncol 2010, 11:155-64

ROLE OF PKC-BETA
PKC-beta expression is reduced in melanoma cell lines and its re-expression inhibits colony formation in soft agar, indicating a potential role of PKC-beta in tumor growth.
Source: Voris JP, Pigment Cell Melanoma Res 2009, Epub ahead of print

VEGF RECEPTOR EXPRESSION
In a large series of melanoma specimens (n=468), VEGFR2 expression was higher in metastatic melanoma, while VEGFR3 expression was higher in primary melanoma.
Source: Mehnert JM, Hum Pathol 2010, 41:375-84

2-DEOXY-D-GLUCOSE AND TRAIL
2-deoxy-D-glucose (2-DG) sensitizes human melanoma cells to TRAIL-induced apoptosis through XBP1-mediated upregulation of TRAILR2.
Source: Liu H, Mol Cancer 2009, 8:122

KIT MUTATION IN MUCOSAL MELANOMA
The Authors report on one case of anal mucosal melanoma positive for activating KIT mutation responding to imatinib and review the literature on similar cases (n=12).
Source: Satzger I, Dermatology 2010, 220:77-81

SORAFENIB + TEMOZOLOMIDE
In a 4-arm phase II RCT (n=167), the median progression free survival for patients on arm A, B, C, and D was 5.9, 4.2, 2.2, and 3.5 months, respectively.
Source: Amaravadi RK, Clin Cancer Res 2009, 15:7711-8

AKT ACTIVATION IN MELANOMA
In human melanoma metastases (n=96), phosphorylated AKT is more frequent in BRAF mutated than NRAS mutated specimens, is almost always associated with PTEN loss and is more frequent in brain metastases.
Source: Davies MA, Clin Cancer Res 2009, 15:7538-46

MEK + CDK4 INHIBITION
Combined inhibition of MEK and CDK4 leads to human melanoma cell apoptosis (in vitro) more potently than either inhibition alone.
Source: Li J, Cancer Invest 2009, Epub ahead of print

FALSE NEGATIVE SENTINEL NODES
In a large series of patients undergoing sentinel node (SN) biopsy (n=2451), the false negative rate was 10.8%, and the survival of patients with false negative SN was not worse than that of patients with true positive SN.
Source: Scoggins CR, Ann Surg Oncol 2010, 17:709-17

HEPARIN-DERIVED OLIGOSACCHARIDES
In a xenogtaft model, heparin-derived 4-18 unit oligosaccharides shows significant anti-melanoma activity.
Source: Kenessey I, Thromb Haemost 2009, 102:1265-73

M8 STILBENE PRECLINICAL ACTIVITY
In a xenogtaft model, 3,3',4,4',5,5'-Hexahydroxystilbene (M8) shows significant anti-melanoma activity.
Source: Paulitschke V, J Invest Dermatol 2009, Epub ahead of print

NANOTECHNOLOGY NEWS
In an in vivo preclinical model, single-walled carbon nanotube-conjugated doxorubicin shows increased therapeutic index against melanoma as compared to doxorubicin alone.
Source: Chaudhuri P, Nanotechnology 2010, 21:025102

DOCETAXEL + TEMOZOLOMIDE
In a retrospective study, this combination regimen has modest activity in patients with metastatic melanoma resistant to first line chemotherapy.
Source: Yoon C, Melanoma Res 2010, 20:43-7

CARBOXYLESTERASE AND CPT-11
Forced expression of carboxylesterase (which converts CPT-11 into SN-38) in neural stem cells significantly increases the anti-melanoma activity of CPT-11.
Source: Gutova M, Curr Stem Cell Res Ther 2009, Epub ahead of print

JWA AND MELANOMA
The microtubule-associated protein JWA suppresses melanoma metastasis in vivo, likely by inhibiting integrin alpha V beta 3 signaling.
Source: Bai J, Oncogene 2009, Epub ahead of print

PARTHENOLIDE PRECLINICAL ACTIVITY
Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro.
Source: Lesiak K, Melanoma Res 2010, 20:21-34

CAMPTOTHECIN ENHANCERS
Both bortezomib (NFkB inhibitor) and KINK-1 (IKKB inhibitor) can enhance the anti-melanoma activity of camptothecin in a preclinical model.
Source: Amschler K, J Invest Dermatol 2009, Epub ahead of print

DIMETHYLFUMARATE (DMF)
DMF increases the anti-melanoma effect of dacarbazine in a xenograft model.
Source: Valero T, J Invest Dermatol 2009, Epub ahead of print

NETRIN-1 AND MELANOMA
Netrin-1 is overexpressed in melanoma as compared to melanocytes and increases melanoma cell migratory potential in vitro.
Source: Kaufmann S, Cell Oncol 2009, 31:415-22

CELASTROL + TEMOZOLOMIDE
Celastrol enhances the anti-melanoma effect of temozolomide in a preclinical model, likely by inhibiting NFkB activity.
Source: Chen M, Mol Cancer Res 2009, 7:1946-53

MELANOMA FIBROBLASTS
Fibroblasts derived from metastatic melanomas can have strong immunosuppressive activity through NK cell modulation.
Source: Balsamo M, Proc Natl Acad Sci USA 2009, Epub ahead of print

HYPOXIA INDUCIBLE FACTOR 1 ALPHA (HIF1-alpha)
HIF1-alpha is overexpressed during melanoma progression and its inhibition has therapeutic potential in a preclinical model.
Source: Mills CN, Mol Cancer 2009, 8:104

THALIDOMIDE + TEMOZOLOMIDE
In a phase II trial (n=64), thalidomide plus temozolomide do not appear to provide a clinical benefit that exceeds dacarbazine alone.
Source: Clark JI, Cancer 2010, 116:424-31

MAINTENANCE BIOTHERAPY
In a phase II trial (n=133), maintenance biotherapy after induction concurrent biochemotherapy appears to improve the survival of patients with metastatic melanoma.
Source: O'Day SJ, J Clin Oncol 2009, 27:6207-12

IMMUNE PROFILE AND MITOTIC INDEX
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.
Source: Bogunovic D, Proc Natl Acad Sci USA 2009, 106:20429-34

c-JUN, PKDK1 AND AKT
c-Jun is a transcriptional regulator of PDK1 expression, which highlights key mechanisms underlying c-Jun oncogenic activity and provides new insight into the nature of upregulated Akt and PKC in melanoma.
Source: Lopez-Bergami P, J Biol Chem 2010, 285:903-13

ROLE OF DE-N-ACETYL-GM3
De-N-acetyl GM3 (a derivative of ganglioside GM3) promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.
Source: Liu JW, Cancer Res 2009, 69:8662-9

TM9SF4 AND MELANOMA CANNIBALISM
Tumor cannibalism is a characteristic of malignancy and metastatic behavior: silencing of TM9SF4 inhibits cannibal activity of human melanoma cells, representing a potential new target for anticancer strategies.
Source: Lozupone F, EMBO Rep 2009, 10:1348-54

NFkB INHIBITION IN UVEAL MELANOMA
Pharmacological inhibition of NFkB reduces proliferation and induces apoptosis of human uveal metastatic melanoma cells in vitro.
Source: Dror R, Invest Ophthalmol Vis Sci 2009, Epub ahead of print

PARP INHIBITION BY PJ-34
Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death in M14 melanoma cell line.
Source: Chevanne M, J Cell Physiol 2010, 222:401-10

3-MARKER PROGNOSTIC SIGNATURE
The expression of 3 biomarkers (NCOA3, SPP1, RGS1) independently predicts survival of patients with melanoma.
Source: Kashani-Sabet M, Clin Cancer Res 2009, 15:6987-92

5-MARKER PROGNOSTIC SIGNATURE
The expression of 5 biomarkers (ATF2, p21/WAF1, p16/INK4A, beta-catenin) independently predicts survival of patients with melanoma.
Source: Gould Rothberg BE, J Clin Oncol 2009, 27:5772-80

GMCSF AND ONCOLYTIC VIRUS
In a phase II clinical trial of a GMCSF-encoding oncolytic herpesvirus, promising tumor response (26%) and survival (52% at 2 years) rates were observed.
Source: Senzer NN, J Clin Oncol 2009, 27:5763-71

BRAF V600E AND MAP2
Oncogenic BRAF V600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and downregulation of transcription repressor HES1.
Source: Maddodi N, J Biol Chem 2010, 285:242-54

ROLE OF Treg CELL DEPLETION
In a RET transgenic mouse model of melanoma, depletion of CD25+Foxp3+ regulatory T cells with anti-CD25 mAb does not prevent tumor development.
Source: Kimpfler S, J Immunol 2009, 183:6330-7

ELESCLOMOL PLUS PACLITAXEL
In a phase II randomized trial (n=81), elesclomol (oxidative stress inducer) improved the therapeutic activity of paclitaxel in terms of progression free survival.
Source: O'Day S, J Clin Oncol 2009, 27:5452-8

VITAMIN D3 SERUM LEVELS
In a cohort of 872 patients, serum levels of vitamin D3 correlated with primary melanoma thickness and patients' survival.
Source: Newton-Bishop JA, J Clin Oncol 2009, 27:5439-44

LOCOREGIONAL RELAPSE AND NODE STATUS
The rate of locoregional (including in transit) metastases in patients with tumor-positive sentinel node (n=141) and patients with palpable nodal involvement (n=178) is similar.
Source: Veenstra HJ, Ann Surg Oncol 2009, Epub ahead of print

CONJUNCTIVAL MELANOMA INCIDENCE
In a Swedish study, the incidence of conjunctival melanoma significantly increased during the period 1960 to 2005.
Source: Triay E, Br J Ophthalmol 2009, 93:1524-8

STAT3 INHIBITION
In a xenograft model, STAT3 inhibition by antisense technology suppresses melanoma growth in vivo.
Source: Yang L, Cancer Biol Ther 2009, 8:2065-72

HYPERTENSION DRUGS AND MELANOMA RISK
In a case-control study (cases=1272), the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was not significantly associated with melanoma risk.
Source: Koomen ER, Cancer Epidemiol 2009, 33:391-5

SKIN SELF-EXAMINATION (SSE)
In a retrospective study (n=321), SSE was associated with decreased tumor thickness (adjusted ratio, 0.75; 95% CI: 0.66-0.85 for ever versus never use).
Source: Pollitt RA, Cancer Epidemiol Biomarkers Prev 2009, 18:3018-23

SENTINEL NODE TUMOR BURDEN
The EORTC Melanoma Group has released the recommendations on the measurement of sentinel node tumor burden for prognostic purpose.
Source: van Akkooi AC, Eur J Cancer 2009, 45:2736-42

SURGERY FOR LIVER METASTASIS
A non randomized study (n=255) showed longer survival for patients undergoing radical versus non radical hepatic resection for melanoma metastasis.
Source: Mariani P, Eur J Surg Oncol 2009, 35:1192-7

BIOMARKERS OF RESPONSE TO IL-2
Serum VEGF and fibronectin can predict clinical response to high dose interleukin-2 (n=59).
Source: Sabatino M, J Clin Oncol 2009, 27:2645-52

RANTES + GP100 VACCINE
In a gene therapy model, vaccination with chemokine RANTES and melanoma antigen gp100 is more effective than with gp100 alone.
Source: Aravindaram K, Gene Ther 2009, 16:1329-39

MODIFIED HEPARINS
Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.
Source: Zhang C, Int J Cancer 2009, 125:2058-65

CDKN2A MUTATION RATE IN FAMILIAL MELANOMA
An Italian study showed that CDKN2A is mutated in 68/204 (33%) families with at least two members affected with melanoma.
Source: Bruno W, J Am Acad Dermatol 2009, 61:775-82

D2-40 DOES NOT PREDICT SENTINEL NODE STATUS
D2-40/S-100 dual immunohistochemistry increases the sensitivity of detection of lymphatic invasion in melanoma but does not predict sentinel lymph node involvement (n=27).
Source: Petitt M, J Am Acad Dermatol 2009, 61:819-28

D2-40 PROGNOSTIC AND PREDICTIVE VALUE
Expression of D2-40 (lymphatic invasion biomarker) in primary melanoma predicts sentinel lymph node status and correlates with survival (n=60).
Source: Petersson F, J Cutan Pathol 2009, 36:1157-63

ROLE OF MMP-13
Stromal expression of matrix metalloproteinase-13 is required for melanoma invasion and metastasis, as demonstrated in a gene knockout model.
Source: Zigrino P, J Invest Dermatol 2009, 129:2686-93

KIT EXPRESSION AND MUTATION
In a series of 173 melanomas, eighty-two percent (12 of 14) of cases positive for KIT mutation showed KIT expression in more than 50% of the cells.
Source: Torres-Cabala CA, Mod Pathol 2009, 22:1446-56

IGFBP7 AND MUTATED BRAF
In melanomas carrying oncogenic mutated BRAF, IGFBP7 is epigenetically silenced; systemically administered recombinant IGFBP7 suppresses the growth of BRAF-positive primary tumors in xenografted mice.
Source: Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14

ADJUVANT IFN FOR UVEAL MELANOMA
In a non randomized trial, low dose adjuvant interferon alpha provides no survival benefit to patients with high risk uveal melanoma.
Source: Lane AM, Ophthalmology 2009, 116:2206-12

PHORBOL ESTER PARADOXICAL ACTIVITY
The tumor-promoting phorbol ester TPA inhibits melanoma growth by inactivation of STAT3 through a PKC activated tyrosine phosphatase.
Source: Oka M, J Biol Chem 2009, 284:30416-23

ADAM10 and L1-CAM
ADAM10 is overexpressed in metastatic as compared to primary melanoma; it is associated with melanoma invasiveness and releases L1-CAM, which is responsible for chemoresistance.
Source: Lee SB, J Invest Dermatol 2009, Epub ahead of print

EAPB0203 PRECLINICAL ACTIVITY
In a xenografted mouse in vivo model, EAPB0203 (a novel imidazo[1,2-a]quinoxaline derivative) is more effective than fotemustine against melanoma.
Source: Khier S, Eur J Pharm Sci 2009, Epub ahead of print

RAPAMYCIN PRECLINICAL ACTIVITY
In a mouse syngeneic model, mTOR inhibitor rapamycin inhibits lung metastasis through downregulation of alpha V integrin expression and upregulation of apoptosis signaling.
Source: Yang Z, Cancer Sci 2009, Epub ahead of print

NESTIN, SOX9 AND SOX10
SOX9 and SOX10 are highly expressed in melanoma and seem to have a regulatory role in Nestin expression; nestin and SOX9 may be negative prognostic markers.
Source: Bakos RM, Exp Dermatol 2009, Epub ahead of print

INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS)
In patients with uveal melanoma (n=90), iNOS expression is not an independent prognostic factor at multivariable survival analysis.
Source: Johansson CC, Int J Cancer 2009, Epub ahead of print

CAFFEIC ACID PHENETYL ESTER (CAPE)
In an mouse melanoma model, CAPE shows anti-melanoma activity in vivo.
Source: Kudugunti SK, Invest New Drugs 2009, Epub ahead of print

BRAF, NFAT AND COX2
Oncogenic BRAF V600E activates NFAT2 and NFAT4 via MEK/ERK signaling, which leads to COX2 upregulation in metastatic melanoma.
Source: Flockhart RJ, Br J Cancer 2009, 101:1448-55

US-GUIDED FNAC AND SNB
Ultrasound-guided fine needle aspiration cytology of sentinel nodes is highly accurate and can lead to significant reduction of SN biopsy procedures.
Source: Voit CA, J Clin Oncol 2009, 27:4994-5000

PARKINSON DISEASE AND MELANOMA
A cohort study (n=157,036) showed a significant association between a positive family history of melanoma and risk of PD (multivariate relative risk = 1.85; 95%CI = 1.2-2.8).
Source: Gao X, Neurology 2009, 73:1286-91

ADH-1 FOR ISOLATED LIMB INFUSION
In a phase I trial (n=16), isolated limb infusion with melphalan combined with ADH-1 (a N-cadherin inhibitor) yielded a high complete response rate (50%).
Source: Beasley GM, Cancer 2009, 115:4766-74

PHOTOACUSTIC FLOW CYTOMETRY
Two color photoacustic flow cytometry with diode laser can reliably detect up to 1 melanoma cell per ml, which can be relevant for searching circulating melanoma cells.
Source: Galanzha EI, Cancer Res 2009, 69:7926-34

SNF5 TUMOR SUPPRESSOR GENE
SNF5, the core subunit of SWI/SNF complex, is downregulated in melanoma, which correlates with poor patients' prognosis; in vitro, SNF5 knockdown causes chemoresistance.
Source: Lin H, Clin Cancer Res 2009, 15:6404-11

MC1R VARIANTS AND MELANOMA RISK
In this case-control study (n=1,185), red hair color (RHC) and non-RHC melanocortin receptor 1 (MC1R) variants were the major contributors for melanoma risk in the German and Spanish population, respectively.
Source: Scherer D, Int J Cancer 2009, 125:1868-75

YM155 PHASE II TRIAL
In this trial (n=34), YM155 (a survivin inhibitor) failed to demonstrate significant anti-melanoma activity.
Source: Lewis KD, Invest New Drugs 2009, Epub ahead of print

MELANOMA THICKNESS TRENDS
An analysis of the SEER database revealed that over the past 20 years the proportion of melanoma in situ has increased, while thick melanoma proportion has remained substantially unchanged.
Source: Criscione VD, J Invest Dermatol 2009, Epub ahead of print

MIR-15B AND MELANOMA
MicroRNA-15b represents is an independent prognostic factor and increases melanoma cell proliferation and survival.
Source: Satzger I, Int J Cancer 2009, Epub ahead of print

LACUNARITY ANALYSIS
Lacunarity analysis (a simple statistical measure used for the analysis of fractal and multi-scaled images) of digitized dermoscopic images could help clinicians to diagnose cutaneous melanoma.
Source: Gilmore S, PLoS One 2009, 4:e7449

CD40L PLUS TLR AGONISTS
In an in vivo mouse melanoma model, nanoparticle-delivered multimeric soluble CD40L DNA show synergistic therapeutic effect combined with toll-like receptor (TLR) agonists.
Source: Stone GW, PLoS One 2009, 4:e7334

EXCISION MARGINS META-ANALYSIS
According to a Cochrane meta-analysis of randomized controlled trials, primary melanoma excision margins (wide vs narrow) do not affect patients' overall survival.
Source: Sladden MJ, Cochrane Database Syst Rev 2009, CD004835

WARNING ON PI-103
In an in vivo mouse melanoma model, PI-103 - a dual PI3K (p110alpha)/mTOR inhibitor - has no synergistic effect with sorafenib (BRAF/CRAF inhibitor), may cause immunosuppression, inhibit apoptosis and ultimately favor tumor growth.
Source: López-Fauqued M, Int J Cancer 2009, Epub ahead of print

KIT AND HIF-1 alpha
c-Kit mutant melanocytes show activation of PI3K pathway that is not sufficient for transformation; combination with HIF-1 forced expression leads to Ras/Raf/Mek/Erk pathway activation and melanocyte transformation.
Source: Monsel G, Oncogene 2009, Epub ahead of print

TYRO3 AND MITF
The receptor protein tyrosine kinase TYRO3 is an upstream regulator of MITF expression; its knockdown shows antimelanoma activity in a xenograft model and acts as a chemosensitizer.
Source: Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30

ROR2 AND WNT5A
The orphan tyrosine kinase receptor ROR2 mediates Wnt5A signaling in metastatic melanoma and its silencing shows antimelanoma activity in an in vivo mouse model.
Source: O'Connell MP, Oncogene 2009, Epub ahead of print

PAEP FUNCTIONAL CHARACTERIZATION
Silencing of PAEP (progestagen-associated endometrial protein) shows anti-melanoma activity in a xenograft model.
Source: Ren S, J Cell Mol Med 2009, Epub ahead of print

EPAC AND MIGRATION
Silencing of EPAC (an effector molecule of cAMP) inhibits melanoma cell migration.
Source: Baljinnyam E, Am J Physiol Cell Physiol 2009, 297:C802-13

MT1 MELATONIN RECEPTOR
MT1 melatonin receptor is expressed in primary melanoma and correlates with tumor thickness.
Source: Danielczyk K, Anticancer Res 2009, 29:3887-95

MITF AND BRAF V600E
In an in vitro model of human melanoma, silencing of MITF synergically increases the cytotoxic effect of BRAF V600E silencing.
Source: Kido K, Cancer Sci 2009, 100:1863-9

TREMELIMUMAB + VACCINE
In a phase I-II trial (n=16), MART-1 peptide-pulsed dendritic cells and tremelimumab resulted in objective and durable tumor responses at the higher range of the expected response rate with either agent alone.
Source: Ribas A, Clin Cancer Res 2009, 15:6267-76

ONCOLYTIC REOVIRUS
In a murine in vivo melanoma model, oncolytic Reovirus increases the antitumor activity of cisplatin.
Source: Pandha HS, Clin Cancer Res 2009, 15:6158-66

ADJUVANT RADIOTHERAPY
In a retrospective study (n=77), adjuvant radiotherapy after lymph node dissection yields a high locoregional control rate, although distant metastases remain the major cause of mortality.
Source: Conill C, Clin Transl Oncol 2009, 11:688-93

SNB RECOMMENDATIONS
The European Association of Nuclear Medicine (EANM) and the EORTC have jointly released the recommendations for sentinel node biopsy in melanoma.
Source: Chakera AH, Eur J Nucl Med Mol Imaging 2009, 36:1713-42

HSV2 MUTANT DeltaPK
The growth defective herpes simplex virus type 2 mutant deltaPK shows significant antitumor activity in a xenograft model of human melanoma.
Source: Colunga AG, Gene Ther 2009, Epub ahead of print

MELANOMA INHIBITORY ACTIVITY (MIA)
MIA protein is highly expressed and secreted by malignant melanoma cells and plays an important role in melanoma development, progression and tumor cell invasion.
Source: Schmidt J, Int J Cancer 2009, 125:1587-94

CAVEOLIN-1
In an in vitro model, caveolin-1 promotes human melanoma progression as indicated by enhanced proliferation, migration, invasion and foci formation in semisolid medium.
Source: Felicetti F, Int J Cancer 2009, 125:1514-22

ARTEMISININ
Artemisinin (an antimalarial drug) reduces human melanoma cell migration by downregulating alpha V beta 3 integrin and metalloproteinase-2.
Source: Buommino E, Invest New Drugs 2009, 27:412-8

FAMILIAL MELANOMA IDENTIFICATION
In this review article, the Authors found that CDKN2A germline mutations (responsible for about 2% of melanomas) are more frequent in individuals with 3 or more primary invasive melanomas.
Source: Leachman SA, J Am Acad Dermatol 2009, 61:677.e1-14

MOESIN AND INVASION
In a 3D model, moesin orchestrates cortical polarity of melanoma cells, which may drive tumor vertical migration instead of superficial spreading.
Source: Estecha A, J Cell Sci 2009, 122(Pt 19):3492-501

MELANOMA REPROGRAMMING
Mouse melanoma cells can be reprogrammed into induced pluripotent stem cells, which suggests that cancer cells remain susceptible to transcription factor-mediated reprogramming.
Source: Utikal J, J Cell Sci 2009, 122(Pt 19):3502-10

PET VERSUS CT FOR STAGING
In a prospective comparison (n=251), PET and CT were equivqlent in upstaging; treatment changed in 19% of patients (79% using both scans, 17% only by PET, 4% only by CT).
Source: Bastiaannet E, J Clin Oncol 2009, 27:4774-80

WT1 AND MELANOMA DIAGNOSIS
Wilms' tumor 1 (WT1) protein expression is not helpful for the diagnosis of skin melanoma in a series of 45 cases.
Source: Rosner K, J Cutan Pathol 2009, 36:1077-82

SILIBININ AND MITOMYCIN-C
In an in vitro model, silibinin (a flavonoid from plant-derived silymarin) protects melanoma cells from mitomycin-C cytotoxicity.
Source: Jiang YY, J Pharmacol Sci 2009, 111:137-46

MELANOMA SPONTANEOUS REGRESSION
A review of the literature on the phenomenon of metastatic melanoma spontaneous regression reveals a total of 76 reported cases since 1866.
Source: Kalialis LV, Melanoma Res 2009, 19:275-82

ESTROGENS AND TUMOR THICKNESS
A retrospective Dutch study (n=687), use of estrogens is not associated with primary melanoma thickness.
Source: Koomen ER, Melanoma Res 2009, 19:327-32

GALLIUM COMPLEX KP46
In an in vitro model, gallium complex KP46 shows strong anti-melanoma activity.
Source: Valiahdi SM, Melanoma Res 2009, 19:283-93

GALECTIN-3 AND PROGNOSIS
Serum levels of galectin-3 may have an independent prognostic value in stage III-IV melanoma patients.
Source: Vereecken P, Melanoma Res 2009, 19:316-20

LAMININ-421 AND MIGRATION
In an in vitro model, antibody blockage of lymphatic endothelial cell laminin-421 inhibits migratory ability of melanoma cells.
Source: Saito N, Pigment Cell Melanoma Res 2009, 22:601-10

FOLATE RECETOR ALPHA AND METHOTREXATE
In an in vitro model, folate receptor mediated sequestration of methotrexate (MTX) in melanosomes may be targeted to overcome melanoma resistance to MTX.
Source: Sánchez del Campo L, Pigment Cell Melanoma Res 2009, 22:588-600

CREB AND CYR61
In an in vivo model, stable silencing of cAMP-response element-binding protein (CREB) expression in human metastatic melanoma cell lines suppresses tumor growth and experimental metastasis by downregulating cysteine-rich protein 61 (CCN1/CYR61) expression.
Source: Dobroff AS, J Biol Chem 2009, 284:26194-206

INDUCING MELANOMA DIFFERENTIATION
Induction of terminal differentiation in melanoma cells by downregulation of beta-amyloid precursor protein (APP) impairs cell proliferation and improves chemosensitivity.
Source: Bothelho MG, J Invest Dermatol 2009, Epub ahead of print

MART1 + P40 VACCINE
In a pilot study (n=14), vaccination with Melan-A/Mart-1 peptide and Klebsiella protein P40 as an adjuvant induced ex vivo detectable tumor antigen specific T cell responses in 6 patients.
Source: Lienard D, J Immunother 2009, Epub ahead of print

NEW MELANOMA ANTIGEN MELOE-2
An additional open reading frame (ORF) on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context.
Source: Godet Y, Cancer Immunol Immunother 2009, Epub ahead of print

LOSARTAN PRECLINICAL ACTIVITY
In an in vivo murine melanoma model, inhibition of angiotensin II receptor 1 (AT1) by losartan limits tumor angiogenesis and growth.
Source: Otake AH, Cancer Chemother Pharmacol 2009, Epub ahead of print

EARLY VS LATE ONSET MELANOMA
Using the SEER database, investigators found epidemiological differences between early and late onset melanomas.
Source: Anderson WF, Cancer 2009, 115:4176-85

CAR-T CELLS PRECLINICAL ACTIVITY
In a xenograft model, immunotherapy of metastatic human melanoma using chimeric antigen receptors (CAR) engineered ganglioside GD2-specific T cells increases the survival of tumor-bearing animals.
Source: Yvon E, Clin Cancer Res 2009, 15:5852-60

GPIbalpha AND METASTASIS
In a mouse in vivo model, platelet glycoprotein Ib alpha (GPIbalpha) inhibition promotes melanoma metastasis.
Source: Erpenbeck L, J Invest Dermatol 2009, Epub ahead of print

PET META-ANALYSIS
A meta-analysis of 24 sudies shows that (18)F-FDG positron emission tomography is not useful to detect regional metastases, but could be useful to detect distant metastases.
Source: Jiménez-Requena F, Eur J Nucl Med Mol Imaging 2009, Epub ahead of print

ERBB4 MUTATIONS
ERBB4/HER4 mutations were found in 19% of individuals with melanoma (n=79); melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with ERBB inhibitor lapatinib.
Source: Prickett TD, Nat Genet 2009, 41:1127-32

SYNTAXIN-7
Using an antibody-based proteomics approach, investigators found that Syntaxin-7 (STX7) is selectively expressed in melanocytes and melanoma.
Source: Strömberg S, J Proteome Res 2009, 8:1639-46

OBESITY AND PROGRESSION
In a mouse melanoma model, obesity enhances melanoma growth in vivo, possibily by upregulation of VEGF pathways.
Source: Brandon EL, Cancer Biol Ther 2009, Epub ahead of print

MENADIONE AND SIAH2
Menadione is a specific inhibitor of SIAH2 ubiquitin ligase; in vivo, it inhibits the growth of xenograft melanoma.
Source: Shah M, Pigment Cell Melanoma Res 2009, 22:799-808

POSITIVE NON-SENTINEL LYMPH NODE (NSLN)
Among node-positive melanoma patients (n=429), presence of a positive NSLN is a highly significant poor prognostic sign, which warrants completion lymph node dissection after a positive SLN.
Source: Ghaferi AA, Ann Surg Oncol 2009, 16:2978-84

DNA REPAIR GENE POLYMORPHISMS
A meta-analysis (cases=4,195) reveals that XPD/ERCC2 single nucleotide polymorphism rs13181 is associated with risk of melanoma development.
Source: Mocellin S, Carcinogenesis 2009, 30:1735-43

MELANOSOMES AND CHEMORESISTANCE
In an vitro model, melanosome dynamics (e.g. biogenesis, density, status and structural integrity) modulates the drug resistance of melanoma cells.
Source: Chen KG, J Natl Cancer Inst 2009, 101:1259-71

PAR1, PAFR AND METASTASIS
Protease-activated receptor-1 (PAR1) and platelet-activating factor receptor (PAFR) induce melanoma cell adhesion molecule (MCAM/MUC18) expression and favor melanoma metastasis.
Source: Melnikova VO, J Biol Chem 2009, 284:28845-55

FKBP51 AND RADIOSENSITIZATION
Inhibition of FK506-binding protein 51 (FKBP51, an immunophilin with isomerase activity) greatly enhances radiotherapy efficacy in a xenograft melanoma model.
Source: Romano S, Cell Death Differ 2009, Epub ahead of print

NEW TNM STAGING SYSTEM
The latest version of the AJCC TNM staging system for cutaneous melanoma has been released (based on 30,946 cases). Main changes: 1) mitotic rate (added); 2) Clark level (removed). Main limit: no molecular biomarker has been implemented. The details are available in the TNM Staging section of the MMMP website.
Source: Balch CM, J Clin Oncol 2009, Epub ahead of print

SYNDECANS AND WNT5A
Heparan sulfate proteoglycans syndecan 1 and 4 are key components of the Wnt5A autocrine signaling, the activation of which leads to increased metastasis of melanoma.
Source: O'Connell MP, J Biol Chem 2009, 284:28704-12

US SCAN FOR PRIMARY THICKNESS
In a small study (n=53), preoperative 10-MHz sonography could discriminate thick (> 1 mm) from thin melanomas with promising accuracy.
Source: Vilana R, AJR Am J Roentgenol 2009, 193:639-43

CHEST X-RAY QUESTIONED
In 248 patients undergoing SNB, preoperative chest X-ray did not identify pulmonary metastasis and did not change planned treatment strategies.
Source: Vermeeren L, J Surg Res 2009, Epub ahead of print

NOVEL PET RADIOTRACER
A new melanoma positron emission tomography (PET) imaging radiotracer has been developed with high tumor-to-body contrast ratio and rapid renal clearance.
Source: Greguric I, J Med Chem 2009, 52:5299-302

4-HYDROXYCOUMARIN PRECLINICAL ACTIVITY
Anticoagulat 4-hydroxycoumarin (4-HC) resulted effective against melanoma in an in vivo mouse model.
Source: Salinas-Jazmín N, Cancer Chemother Pharmacol 2009, Epub ahead of print

LUMCORIN AND MIGRATION
In an in vitro study, lumcorin (a peptide derived from human lumican) inhibits melanoma migration.
Source: Zeltz C, FEBS Lett 2009, 583:3027-32

MELANOMA DETECTION ABILITY
An Australial study showed that the ability of skin cancer clinics to detect melanoma is similar to that of mainstream general practice and worse than specialist practice.
Source: Hansen C, J Am Acad Dermatol 2009, 61:599-604

WHOLE BRAIN RADIOTHERAPY (WBRT)
A small retrospective study (n=51) suggests that patients with brain metastases from melanoma receiving WBRT alone may benefit from dose escalation beyond 10x3 Gy.
Source: Rades D, Int J Radiat Oncol Biol Phys 2009, Epub ahead of print

MELANOMA EPIDEMIC
In a study conduced in East Anglia, melanoma incidence increased from 9.39 to 13.91 cases/100,000/year, while overall mortality only increased from 2.16 to 2.54 cases/100,000/year.
Source: Levell NJ, Br J Dermatol 2009, 161:630-4

DTIC +/- PF3512676
In a phase II-III RCT, the addition of CpG oligodeoxynucleotide PF-3512676 does not add significant tumor response advantage to dacarbazine alone.
Source: Weber J, Cancer 2009, 115:3944-54

HLA MOLECULES EXPRESSION
Investigators have assessed the expression of HLA class I and II molecules in a large panel of human melanoma cell lines.
Source: Mendez R, Cancer Immunol Immunother 2009, 58:1507-15

ADHESION MOLECULES EXPRESSION
Investigators have assessed the expression of adhesion molecules and ligands for receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.
Source: Casado JG, Cancer Immunol Immunother 2009, 58:1517-26

IPILIMUMAB PLUS BUDESONIDE
A phase II RCT showed that budesonide (an oral non-absorbed corticostroid) does not prevent dyarrhea in patients taking anti-CTLA4 ipilimumab.
Source: Weber J, Clin Cancer Res 2009, 15:5591-8

CXCL8 AND ITS RECEPTORS
In a human melanoma preclinical model, CXCL8 induces cell proliferation and angiogenesis; inhibition of its receptors (CXCR1 and CXCR2) shows promising therapeutic potential.
Source: Gabellini C, Eur J Cancer 2009, 45:2618-27

NBDHEX PRECLINICAL ACTIVITY
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) induces JNK activation and apoptosis, and appears effective against human melanoma in both in vitro and in vivo preclinical models.
Source: Pellizzari Tregno F, Eur J Cancer 2009, 45:2606-17

TIL AND SENTINEL NODE STATUS
An Italian study (n=404) showed a significant correlation between the presence of tumor infiltrating lymphocytes (TIL) and sentinel node status.
Source: Mandalŕ M, Eur J Cancer 2009, 45:2537-45

News Archive